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Summary 50 
We studied how intratumoral genetic heterogeneity shapes tumor growth and therapy response 51 
for isocitrate dehydrogenase (IDH)-wildtype glioblastoma, a rapidly regrowing tumor. To this end, 52 
we inferred the evolutionary trajectories of matched pairs of primary/relapsed tumors based on 53 
deep whole-genome-sequencing. This analysis suggests both a distant origin of de novo 54 
glioblastoma, up to seven years before diagnosis, and a common path of early tumorigenesis, with 55 
one or more of three events (chromosome 7 gain, 9p loss or 10 loss) at tumor initiation. TERT 56 
promoter mutations often occurred later as a prerequisite for rapid growth. In contrast to this 57 
common early path, relapsed tumors acquired no stereotypical pattern of mutations and typically 58 
regrew from oligoclonal origins, suggesting sparse selective pressure by therapeutic measures.  59 
 60 
Significance  61 
Many tumors consist of genetically diverse subclones, which are thought to reflect cancer 62 
evolution. Indeed, we uncover large genetic diversity in tissue samples of aggressive brain tumors, 63 
IDH-wildtype glioblastomas, obtained at primary and recurrent surgical resection. Surprisingly, 64 
however, all these diverse tumors (which also belong to the known four subgroups) map onto a 65 
common path of early tumorigenesis where characteristic driver mutations are acquired by losses 66 
or gains of (parts of) chromosomes. Mutation rates suggest that these tumor-initiating events 67 
occur several years before diagnosis. Other common drivers, including TERT promoter mutations, 68 
often follow and may allow the tumor to grow to detectable size. Further genetic diversification 69 
appears to contribute little to the regrowth of the tumors after therapy. 70 
  71 
 4 
Introduction 72 
Tumors are typically heterogeneous mixtures of genetic subclones. Analyses of subclonal tumor 73 
evolution have focused on oncogenic drivers, which may inform the search for more effective 74 
therapeutic approaches (Greaves and Maley, 2012). However, recent studies across several cancer 75 
entities (Williams et al., 2016) or across many locations within one tumor (Ling et al., 2015) have 76 
questioned this idea by arguing that intra-tumoral genetic heterogeneity is often due to neutral 77 
(passenger) mutations. As tumor growth as a whole is caused by driver mutations, these findings 78 
concern the fundamental, but poorly understood, question of the relation between tumor growth 79 
and genetic evolution.  80 
Here we address this question for the genetic evolution of glioblastoma. Glioblastomas are 81 
the most frequent malignant primary brain cancers in adults that rapidly recur after initial therapy 82 
and thus rank among the human malignancies with the highest mortality (with a 5-year survival 83 
rate of only 6%; Ostrom et al., 2016). Thus, it is of particular clinical interest whether standard 84 
chemoradiotherapy exerts selective pressure on the evolution of the relapse tumor. With advances 85 
in whole-genome sequencing, genetically distinct subclones within glioblastomas have been 86 
identified. Several studies have suggested that branched evolution of the tumor contributes to 87 
treatment failure (Francis et al., 2014; Hu et al., 2017; Meyer et al., 2013; Patel et al., 2014; Snuderl et 88 
al., 2011; Sottoriva et al., 2013; Yates et al., 2015). In this view, therapeutic intervention, typically 89 
consisting of neurosurgical tumor resection followed by chemoradiotherapy with temozolomide 90 
(TMZ) (Weller et al., 2017) may select resistant subclones from residual tumor cells which quickly 91 
regrow (Gerlinger and Swanton, 2010; Nathanson et al., 2014; Qazi et al., 2017). Moreover, exome 92 
sequencing of pairs of isocitrate dehydrogenase (IDH)-mutant diffuse gliomas of World Health 93 
Organisation (WHO) grade II that recurred as WHO grade III or IV gliomas suggests that therapy 94 
may drive tumor evolution to more malignant stages, with 60% of patients receiving TMZ reported 95 
to show a strong increase in tumor mutation rate (Johnson et al., 2014). To investigate whether 96 
these scenarios of progressive tumor evolution driven by cytotoxic therapy also apply to IDH-97 
wildtype tumors that were already glioblastomas at initial diagnosis (de novo glioblastomas), we 98 
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have utilized the distribution of clonal and subclonal mutations to infer both the genetic evolution 99 





Mutation patterns in primary and recurrent glioblastomas are largely similar 105 
To assess the genetic evolution of glioblastomas, we analyzed the genomes, transcriptomes and 106 
methylomes in paired primary (untreated) and recurrent (following initial treatment) tumor tissue 107 
samples from patients with de novo glioblastomas, isocitrate dehydrogenase wildtype (IDHWT), 108 
World Health Organization (WHO) grade IV. In total, paired tissue samples from 50 patients were 109 
included, the majority of whom had received radiotherapy combined with concomitant and 110 
maintenance temozolomide (TMZ) chemotherapy after neurosurgical resection (Figure 1A and 111 
Table S1). We chose tumor pairs from 21 patients as a discovery set and sequenced whole genomes 112 
of both samples (149x average coverage) and a matched blood control (78x average coverage), as 113 
well as the transcriptomes of primary and recurrent tumors (Figure 1B). The median tumor cell 114 
contents were 80% and 78% for primary and recurrent samples, respectively (Figure S1A). 115 
Transcriptome and methylome analyses indicated that the vast majority of non-tumor cells were 116 
infiltrating immune cells, particularly monocytes (Figure S1B,C) (cf. Wang et al., 2017). In addition, 117 
we sequenced a panel of 50 glioma-associated genes in primary and recurrent tumor pairs from 43 118 
IDHWT glioblastoma patients, including 14 of the 21 patients included in the whole genome 119 
sequencing (WGS) discovery set (Table S1). Assessing genome-wide DNA methylation patterns in 120 
both sets with Illumina 450k/EPIC bead chip arrays, we found the previously described major 121 
glioblastoma subgroups by unsupervised clustering (Capper et al., 2018; Sturm et al., 2012) (Figure 122 
1B). We noted that samples classified as mesenchymal subtype had comparatively low tumor 123 
content, suggesting that this particular classification may be influenced by a high fraction of non-124 
tumor cells. When excluding subtype switches involving the mesenchymal subtype, we found that 125 
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90% of primary and recurrent tumor pairs had a stable methylation subtype, while the remainder 126 
switched from the RTKII to the RTKI group (Figure 1B, Figure S1D). 127 
Whole genome sequencing yielded a median mutational burden of 12,800 somatic single 128 
nucleotide variants (SNVs) and small insertions/deletions (indels) per tumor, and most samples had 129 
a mutation count in this order of magnitude (Figure 1C). One primary and four recurrent tumors 130 
had vastly more mutations (>105), which included somatic mutations in DNA mismatch repair 131 
genes (MLH1 or MSH6), consistent with a hypermutation genotype. Apart from these hypermutated 132 
cases, primary and recurrent tumor samples had comparable numbers of mutations (p value = 0.77, 133 
two-sided Welch two sample t-test). On average, about as many mutations were shared between 134 
primary and recurrent samples as were private to either sample (Figures 1D and 1E). The shared 135 
mutations were dominated by the clock-like mutational signature 1 (Figure 1F; classification 136 
according to COSMIC; Alexandrov et al., 2013; Forbes et al., 2016). The pattern of private mutational 137 
signatures in both primary and non-hypermutated recurrent tumors were shifted away from 138 
signature 1 and included signatures due to defective double-strand break repair by homologous 139 
recombination (signature 3), defective mismatch repair (signature 15 and signature 26) and one of 140 
unknown etiology (signature 5) (Figure 1G). The hypermutated tumors were all dominated by 141 
mutational signature 11 (Figure 1H), described as being linked to TMZ treatment (Alexandrov et al., 142 
2013). The similarity of mutation counts and signatures in paired primary and recurrent tumors 143 
suggests that the major part of the genetic evolution occurred prior to the diagnosis of the primary 144 
tumor. Only the comparatively small subgroup of hypermutated tumors showed a global 145 
mutational signature of cytotoxic treatment. 146 
 147 
Paucity of common mutations in recurrent tumors 148 
We identified recurrent driver mutations in SNVs, indels, copy number variations (CNVs) and 149 
structural variants (SVs) [several of which are druggable (Gröbner et al., 2018), Figure S2A, 150 
Methods]. Driver mutations detectable in tumors of at least three patients were found in the 151 
coding regions of 28 genes, in 13 non-coding RNAs and the TERT promoter region (Figure 2A). All 152 
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21 tumor pairs harbored at least one of three chromosomal gains or losses: (i) loss of chromosome 153 
10 or the 10q arm, including the PTEN locus; (ii) loss of chromosome arm 9p or focal deletion of the 154 
CDKN2A/B locus; (iii) complete or partial gain of chromosome 7, including the EGFR locus (Figure 155 
2A, B). The majority of 9p losses and focal deletions of CDKN2A/B were homozygous. Chromosome 156 
10 or 10q loss was always hemizygous but in 75% of the tumor samples accompanied by a 157 
mutation in the remaining PTEN allele. Chromosome 7 gains were frequently (58%) accompanied 158 
by focal amplifications of the EGFR locus (which may be extrachromosomal in the form of double 159 
minutes; deCarvalho et al., 2018). When present, focal EGFR amplification occurred in all but one 160 
case already in the primary tumor and was lost in the recurrent samples in 27% of the cases. 161 
Moreover, almost half of the EGFR amplifications (44%) co-occurred with the active variant 162 
EGFRvIII (generated by deletion of exons 2-7; Brennan et al., 2013), and in three samples 163 
EGFR had an interchromosomal translocation into the vicinity of a superenhancer (Figure 2C). 164 
In several cases chromosomal gains increased (Figure 2D) or decreased (Figure 2E) in complexity 165 
between primary and recurrent tumors.  166 
TERT promoter mutations were found in all but one primary sample (in the latter case, it 167 
was detected neither in the WGS nor the panel sequencing data). In contrast to the above 168 
chromosomal gains/losses and the TERT promoter mutations, the most frequent coding mutations 169 
(in PTEN, EGFR or TP53) were present in a subset of the tumors only. We observed comparable 170 
distributions of SNVs and small indels in these genes, as well as TERT promoter mutations, in the 171 
independent validation set (Figure S2B). Moreover, mutations in thirteen non-coding RNAs were 172 
recurrent (Figure 2A). The occurrence of widespread driver mutations in primary tumors that are 173 
maintained in the corresponding recurrent tumors (PTEN, CDKN2A/B, EGFR, TERT) contrasted with a 174 
paucity of common mutations newly detected in the recurrent tumor samples. Except for 175 
mutations in the mismatch repair gene MSH6 and in the non-coding RNA XIST, which were 176 
enriched in the hypermutated recurrent samples, no recurrent mutations were preferentially found 177 
upon glioblastoma recurrence. Moreover, hypermutated tumors have a higher probability for 178 
recurrence of mutations by chance. There were, however, several cases of parallel evolution in both 179 
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the discovery and the validation set. We found different mutations in pairs of primary and recurrent 180 
samples for the following eight driver genes: EGFR (5 pairs), ARID1A, AC005154.6, KCNQ1OT1, PTEN, 181 
PTPN11, TSIX, XIST (one pair each). 182 
 183 
Genetic evolution of glioblastoma shows a common pattern across DNA methylation 184 
subtypes 185 
To understand how the mutation patterns in primary and recurrent glioblastomas arise, we 186 
inferred evolutionary histories for the individual sample pairs. We determined for each sample the 187 
allele frequencies of SNVs and indels (variant allele frequencies, VAFs) at non-amplified loci. 188 
Mutations present in both primary and recurrent tumor samples showed a wide range of VAFs 189 
(Figure 3A). Many shared mutations will have arisen comparatively early in tumor development 190 
and will therefore be clonal in both samples. Based on the read coverage of a given locus, we 191 
tested with a binomial model whether a measured VAF is compatible with sampling from a VAF of 192 
50%, implying that the respective allele is clonal. Most VAFs were indeed compatible with clonality. 193 
While this test minimizes erroneous assignment of a mutation as subclonal, we found subclonality 194 
in both primary and recurrent samples for 12% of shared mutations (Figure 3A, red dots). An 195 
additional 7% of mutations were identified as clonal in the primary tumor and subclonal in the 196 
recurrent tumor (Figure 3A, orange dots). This outcome is not possible for a tumor with a single 197 
origin and hence was most likely due to undersampling of the primary tumor, effectively 198 
augmenting the count of subclonal mutations.  Finally, a transition from subclonality in primary to 199 
clonality in the recurrent tumors is suggested for 11% of shared mutations (Figure 3A, blue dots). 200 
However, this outcome is unlikely to be the result of genetic evolution; it will rather encompass 201 
cases where the recurrent tumor has been undersampled (STAR Methods, Subclonality test) and 202 
few cases where surgical resection retained a particular subclone that then forms a clonal relapse 203 
tumor (see Figure 3H below). Taken together, the VAF analysis indicates extensive subclonality of 204 
shared mutations in pairs of primary and recurrent glioblastoma tissue samples. 205 
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 Subclonality is informative on tumor evolution. To uncover this information, we mapped 206 
the observed intratumoral genetic heterogeneity onto the subclonal phylogeny of primary and 207 
recurrent tumors. We combined SNVs and CNVs to this end, developing a likelihood-based 208 
multinomial model that jointly infers genetically distinct subpopulations and their phylogenetic 209 
relationships from the sequencing read count distribution over all mutated loci (Figures 3B and 210 
S3A, B). We assessed the robustness of our algorithm on simulated data with characteristics of the 211 
measured data (150x coverage and tumor cell contents between 50% and 100%) and found 212 
reliable detection of even small clones (5% clone size detected with >80% sensitivity) and faithful 213 
inference of subclonal phylogenies (Figure S3C-L). We then applied subclonal inference to the 214 
measured data, treating normal tissue as an additional subclone, and found that the estimated 215 
tumor cell content closely agreed with purity estimates from ACEseq (CC = 0.95, Figure S3M). Thus 216 
our likelihood-based inference method performed well with simulated data and reproduced the 217 
independent estimate of tumor cell content in the actual data.  218 
We determined the subclonal structure jointly for pairs of primary and recurrent tumor 219 
samples and typically resolved two to three subclones per sample (Figure 3C), with a clear 220 
hierarchy of clone sizes (Figure 3D). Allowing for up to five subclones per tumor sample did not 221 
alter the best-fit tree in all but two cases; in the latter two cases additional subclones were added 222 
within the already existing tree structure. Thus the resolution of up to three subclones per sample 223 
allowed reliable placement of driver mutations in tumor phylogenies.  224 
In more than two thirds (15/21) of the sample pairs, the recurrent tumor originated from 225 
more than one clone of the primary tumor (oligoclonal origin of the relapse; Figure 3F,G and Figure 226 
S4A-N); this oligoclonal relapse scenario included all hypermutated cases. Figure 3E introduces the 227 
layout of the phylogenetic trees, and Figure 3F shows a typical example with oligoclonal origin of 228 
the relapse tumor. Note that, due to limited sampling, the evolution of a recurrent tumor subclone 229 
in the inferred phylogenetic trees does not start directly with the corresponding subclone in the 230 
primary tumor but, instead, both subclones have an unobserved common ancestor. In the example 231 
tree (Figure 3F), one allele of PTEN was lost (chromosome 10 loss) and the other one was 232 
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inactivated by a mutation, before subclonal branching became evident. Subclonal evolution in the 233 
primary tumor added further potential drivers, notably a partial gain of chromosome 7 (incl. EGFR) 234 
and mutations in the TERT promoter, BRAF (D594G) and TSIX. The recurrent tumor arose from two 235 
subclones of the primary tumor and showed further, subclone-specific, driver mutations. Notably, 236 
the subclones of the recurrent tumor acquired two different mutations in LINC00343 in parallel. 237 
Figure 3G depicts an extreme case of oligoclonal relapse where no further recurrent drivers 238 
developed within 307 days between primary and recurrent resection of the tumor (median time 239 
span between initial diagnosis and relapse 284 days). In the minority of cases (6/21) the relapse 240 
tumor had a monoclonal origin (Figure 3H and Figure S4O-S). However, this might be partially due 241 
to taking experimental samples and, indeed, we found only one clear example of linear evolution 242 
of the recurrent tumor, with several new driver mutations being acquired over a comparatively 243 
large time span of ~22 months between primary and secondary resection (Figure 3H). In this case, 244 
the evolutionary time, measured by the number of mutations between the most recent common 245 
ancestor of the subclones in the primary tumor and the most recent common ancestor of the 246 
relapse subclones was indeed comparatively large (~5000 mutations). In stark contrast to this 247 
unique case, all other tumor pairs had identical, or very similar, evolutionary times of emergence of 248 
primary and relapse subclones (Figure 3I). Hence recurrent tumors mainly emerged from already 249 
established heterogeneity of the primary tumor and only moderately added to that. This common 250 
pattern of glioblastoma evolution was independent of DNA methylation subtype. Moreover, we 251 
specifically analyzed the methylation status of the MGMT promoter associated with response to 252 
TMZ therapy (Hegi et al., 2005) and found an apparently random distribution of methylated 253 
and unmethylated promoters between the two groups of oligoclonal and monoclonal relapse 254 
origins (i.e., 21% probability to choose the specific distribution observed at random). The 255 
common pattern of glioblastoma evolution allowed us to derive a consensus phylogeny over all 256 
analyzed tumors. To this end, we walked down the phylogenetic trees from the common stem and 257 
scaled branch thickness according to the number of branch occurrences over all trees, revealing a 258 
typical pattern of each primary subclone spawning a corresponding relapse subclone (Figure 3K). 259 
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The frequency of recurrent mutations declined rapidly from the common stem towards the 260 
branches, suggesting that therapeutic measures do not drive preferential resistance scenarios.    261 
 262 
Copy number variations precede single-nucleotide variations as oncogenic drivers 263 
Clonal mutations (present in all cells of a given primary and recurrent tumor sample) map to the 264 
common stem of the phylogenetic tree and, for each tumor, contain recurrent driver mutations. 265 
These drivers reached clonality due to their early origin in the evolution of the tumor. Further 266 
driver mutations were subclonal and hence originated more recently than the drivers in the stem. 267 
The majority of subclones in relapsed tumors (77%) showed additional driver mutations that were 268 
not found in the primary tumor samples, indicating ongoing genetic evolution.  269 
We found strong overrepresentation of gain of chromosome 7, loss of chromosome arm 270 
9p/focal loss of CDKN2A/B and loss of chromosome 10/10q in the common stem of the 271 
phylogenetic trees, with at least one of these chromosomal gains or losses being clonal in 20/21 272 
tumor pairs (Figure 4A). The single tumor, where none of these chromosomal aberrations was 273 
clonal, harbored two recurrent mutations (as in Figure 2) at the clonal level, a frameshift insertion in 274 
PTEN and a clonal SNV in exon 7 of TP53 (Pro>Ser; aa 278). The most prominent oncogenes on the 275 
altered chromosomes are EGFR (Chr. 7), CDKN2A/B (Chr. 9) and PTEN (Chr. 10), suggesting that 276 
mutations and/or copy number variations in these three genes define the minimal set of driver 277 
mutations from which at least one, and frequently two or all (81%), occur in the stem of each 278 
analyzed tumor. Hence these mutations might be early tumorigenic events.  279 
In contrast to the CNVs, most recurrent SNVs were preferentially subclonal, with the 280 
exceptions of mutations in TP53, PTEN, EGFR and the TERT promoter (Figure 4B). Notably, most 281 
clonal PTEN mutations (7/10) co-occurred with a loss of the other PTEN allele. Mutations in the TERT 282 
promoter occurred in all but one of the 42 primary and recurrent samples, but, remarkably, were 283 
subclonal in 33% of them. Of note, the read coverage of the GC-rich TERT promoter was uniformly 284 
high (123x on average), allowing accurate VAF estimation; moreover, comparison of the VAF 285 
distribution of the TERT promoter mutations with a control set of heterozygous germline 286 
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mutations, including a germline SNP in the  TERT promoter region, clearly showed significant 287 
subclonality in the former (Figure S5A-D). Nevertheless, in all but one case subclonal TERT 288 
mutations occurred in the primary tumor. In addition to canonical TERT promoter mutations 289 
reported previously, we also found exclusively ‘non-canonical’ promoter mutations in two tumors 290 
(Figure 4C). These tumors also had clonal mutations in ATRX, which inhibits alternative telomere 291 
lengthening (exonic frameshift generating a premature stop codon). Analyzing one such case in 292 
detail, we found that the ATRX mutation likely supported tumor growth, as the protein was lost 293 
(Figure S5F), whereas the non-canonical TERT promoter mutation did not increase transcript levels 294 
compared to non-tumor brain tissue (Figure S5G). These and further data (Figure S5H) are 295 
consistent with the view that ATRX mutations and canonical TERT promoter mutations are 296 
independent mechanisms to support survival of proliferating tumor cells. 297 
 Taken together, the placement of mutations on the phylogenetic trees indicates 298 
characteristic patterns of their occurrence: Copy number variations in chromosomes 7, 9 or 10 299 
generally took place early in the evolution of the tumor while TERT promoter mutations were often 300 
acquired subsequently in primary tumors, remaining subclonal in one third of them. The absence 301 
of mutations that are characteristic for recurrent tumors may indicate that little directed selective 302 
pressure is exerted by chemotherapy and/or radiotherapy. 303 
 304 
Large selective advantage of TERT promoter mutations 305 
We reasoned that combining data on the number of somatic mutations accumulated during tumor 306 
evolution with estimates of the characteristic tumor size upon primary resection and the somatic 307 
mutation rate will yield insight into the evolution of IDHWT glioblastoma. Tumor growth results 308 
from the balance of cell proliferation and death rates while the bulk of mutations is assumed to 309 
occur during cell proliferation (Figure 5A). A human brain tumor of 20 cubic centimeters or larger 310 
(Goldberg-Zimring et al., 2005) corresponds to at least 109 – 1010 cells (Del Monte, 2009; DeVita et 311 
al., 1975; Milo et al., 2010). The number of somatic mutations in a primary tumor cell (M) is the sum 312 
of mutations that were already present when the first oncogenic event occurred in the founder cell 313 
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(M1) and the mutations that occurred subsequently during tumor evolution (M2). Hence to obtain 314 
the mutation number of interest, M2, we need to subtract M1 from M. We get conservative 315 
estimates of M and M1 from the WGS data as follows: M1 is taken as the number of mutations in the 316 
tumor stem (clonal mutations, MC) while M is taken as the average number of mutations in all 317 
subclones of the primary tumor; hence the clonal and subclonal mutation counts provide a 318 
measure of evolutionary time (Figure 5B). Excluding hypermutated cases, we find a median of M2 = 319 
2300 mutations accumulated during the evolution of the primary tumor (Figure S5I). Mutations 320 
that are found at subclonal level fixed through cell divisions, and we assume a constant rate of 321 
mutation accumulation per division. The average somatic mutation rate was taken as 2.6 x 10-9 per 322 
base-pair and division (Milholland et al., 2017), which corresponds primarily to the clock-like 323 
mutation signature in our data (signature 1, Figure 1F). We observed a drop of the signature 1 324 
contribution by 77% between clonal mutations (tumor stem) and late mutations (at the tips of the 325 
phylogenetic trees; Figure S5K), which implies an increase in mutation rate during tumor evolution 326 
provided that the clock-like rate is constant. Therefore, we accounted for the possibility of a 327 
fourfold increase of the somatic mutation rate during tumor evolution. To accumulate 2300 328 
mutations with this range of mutation rates (2.6 x 10-9 to 10.6 x 10–9 mutations per base-pair and 329 
division), 66 to 268 cell divisions are required. To then reach a realistic tumor size of 109 – 1010 cells, 330 
most daughter cells (69-92%) must have died after cell division (Figures 5C and S5L). Hence, the 331 
combined balance of cell numbers and somatic mutations implies that massive cell death occurs 332 
during glioblastoma evolution and, on average, only 8-31% of cell divisions lead to tumor growth 333 
(Figure S5L). 334 
 The estimated high fraction of cell death is an average over the entire time course of 335 
evolution up to the resected primary tumor. Our WGS data show that a core set of pro-proliferative 336 
driver mutations (CNVs affecting CDKN2A/B, PTEN, or EGFR) occurred early during tumor evolution. 337 
TERT promoter mutations were also found in all but one primary tumor but their frequent 338 
subclonality indicates that they may occur a considerable time after tumor initiation. These 339 
mutations are not pro-proliferative but rather have been described as a key event that extends 340 
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cellular life span by healing short telomeres (Chiba et al., 2017). We modeled this scenario by 341 
assuming an initial growth regime with massive cell death before the TERT promoter mutation and, 342 
thereafter, a second regime with reduced cell death (Figure 5D). This model reproduced the 343 
observed distribution of tumors with clonal and subclonal TERT promoter mutations (focusing on 344 
the two canonical base pair substitutions in the TERT promoter (chr5:1295228 / chr5:1295250)). This 345 
fit was obtained when these mutations reduced the cell death rate by 6-28% (Figure 5E and S5N,O), 346 
corresponding to a selective advantage of 0.03 – 0.16. While this is an upper estimate because 347 
further mutations may have contributed to reducing cell death, the frequency of TERT promoter 348 
mutations is not matched by any other subclonal mutation, thus suggesting that other mutations 349 
are unlikely to have been major contributors. Notably, the selective advantage of TERT promoter 350 
mutations is larger than the average number for driver mutations (0.004 (Bozic et al., 2016)). 351 
 Finally, we estimated the time duration between the emergence of the founder cell and 352 
tumor diagnosis. To this end, we determined the average division rate of the tumor cells by 353 
dividing the number of mutations occurring after primary resection by the mutation rate and the 354 
time between primary and secondary resection. This yielded a lower bound of tumor cell division 355 
rate of approximately once in ten days. With the number of cell divisions given above that establish 356 
the primary tumor, we find that the founder cell emerges approximately two to seven years prior to 357 
diagnosis (Figure 5F). This range indicates that IDHWT glioblastomas may undergo several years of 358 
evolution before being detected.  359 
 360 
Discussion 361 
The fast and incurable tumor recurrence in adult IDHWT glioblastomas underlines the need for 362 
novel, more effective treatment approaches. To dissect the genetic basis of recurrence, we 363 
reconstructed the evolutionary histories of matched pairs of primary and recurrent IDHWT 364 
glioblastomas, spanning the most common DNA methylome-based tumor subtypes. We found 365 
that the vast majority of recurrent tumors regrew from multiple genetic subclones in the primary 366 
tumors, thus reflecting the existing heterogeneity at the time of resection. This contrasts with the 367 
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previous suggestion of “clonal replacements” in the recurrent tumor under selective pressure 368 
(Wang et al., 2016). However, in this previous study individual phylogenetic trees linking primary 369 
and recurrent tumors were not derived. In our view, quantitative phylogenetic analysis is critical to 370 
evaluate the effects of genetic drift (i.e., accumulation of neutral mutations) in the context of partial 371 
sampling of the tumors. These two factors, drift and partial sampling, make related subclones in 372 
primary and recurrent tumors appear to branch off from a common progenitor that was not 373 
present in the actual samples. Nevertheless, the recurrent subclone is most likely a direct 374 
descendant of the respective primary subclone, with the drawn samples just differing by neutral 375 
mutations. Our data contrast with the description by Kim et al. (2015) of divergent glioblastoma 376 
recurrences that share few genetic alterations with the primary tumor and originate from cells that 377 
branched off early during tumorigenesis. This was associated with regrowth of the tumor in a 378 
location distant from the original lesion. In our study, 90% of the tumors regrew in the same 379 
location as the primary tumor. Therefore, the common pattern of clonal evolution identified here 380 
may be characteristic of locally regrowing glioblastomas. 381 
Our findings indicate that standard therapy exerted little selective pressure on most 382 
recurrent tumors (with the possible exception of the few hypermutated cases). Consistent with this 383 
idea, the vast majority of driver mutations were acquired prior to initial diagnosis and only few 384 
drivers (in two of 21 cases: none) were acquired after initial treatment. The only gene recurrently 385 
mutated in non-hypermutated relapse tumors was the non-coding RNA XIST, which has previously 386 
been suggested as a driver in glioblastoma (Cheng et al., 2017; Yao et al., 2015). The paucity of 387 
newly acquired driver genes in recurrent tumors contrasts with progressive evolution observed in 388 
low grade glioma (Johnson et al., 2014), indicating that IDHWT glioblastomas attained their full 389 
aggressiveness already prior to initial diagnosis.  390 
Combining data on genetic evolution and tumor growth, we inferred that IDHWT 391 
glioblastomas originated several years prior to diagnosis, suggesting that they undergo prolonged 392 
evolution without causing clinical symptoms. Indeed, we uncovered a common path of early 393 
tumorigenesis amongst our cohort: all tumors harbored at least one clonal copy number change in 394 
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EGFR (gain of chromosome 7), CDKN2A/B (loss of chromosome 9p or focal deletion) or PTEN (loss of 395 
chromosome 10/10q, with one tumor having a PTEN mutation instead of a loss). The observation 396 
that clonal 9p loss/focal deletion of CDKN2A/B always occurred in conjunction with chromosome 7 397 
gain or 10/10q loss indicates that the former does not take place before the latter. Our inference of 398 
an early evolutionary origin of these chromosomal gains and losses is consistent with the overall 399 
abundance of these events in the respective TCGA cohort of 590 patients (Brennan et al., 2013; 400 
Grossman et al., 2016) and further studies (Sottoriva et al., 2013; Gerstung et al., 2017; Ozawa et al., 401 
2014; Brastianos et al., 2017). It has also been suggested that TERT promoter mutations are very 402 
early events in IDHWT glioblastomas (Barthel et al., 2018). We found that TERT promoter mutations, 403 
although acquired in the primary tumor, were subclonal in one third of our cohort. The subclonal 404 
resolution of our data places TERT promoter mutations at a subsequent stage of tumorigenesis, as 405 
has recently been suggested also for other tumors (Juratli et al., 2017, Landa et al., 2016). However, 406 
as TERT promoter mutations occur in all tumors (except for one primary sample), they appear to be 407 
associated with a selective advantage and, indeed, have reached clonality in two thirds of the 408 
tumors. During treatment, some (2/7) of the tumors with a subclonal VAF of the TERT promoter 409 
mutation progressed to clonality, but there was no overall increase in the respective VAFs that 410 
remained subclonal. Recent studies have linked TERT promoter mutation to better response to 411 
alkylating chemotherapy and longer patient survival in the subgroup of IDHWT glioblastomas with 412 
MGMT promoter methylation (Arita et al., 2016; Nguyen et al., 2017), raising the interesting 413 
question of how chemotherapy may modulate the abundance of subclones depending on their 414 
mutation spectrum. Mutations in many non-coding RNAs were recurrent and often also clonal. 415 
Mutations in four of these, HOTTIP, SNHG14, KCNQ1OT1 and XIST, have previously been implicated 416 
in cancer (Cheng et al., 2017; Jing et al., 2017; Wang et al., 2018; Yao et al., 2015). Mutations in XIST 417 
were also found in male samples and hence were not restricted to the inactive X chromosome 418 
(Jäger et al., 2013).  419 
It is interesting to compare our finding that the mutated cell of origin of glioblastoma arose 420 
up to several years before diagnosis with reports of glioblastoma or high-grade glioma patients 421 
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who received an MRI scan because of new-onset seizures. In several instances, patients had mild 422 
abnormalities (hyperintense areas) or no abnormal findings in the MRI but then progressed to 423 
glioblastoma or high-grade glioma within several months (e.g., Nishi et al., 2009; Landy et al., 2000). 424 
Our estimate of the time of glioblastoma evolution relies on the count of somatic mutations and 425 
hence starts from the undetectable cell of origin. Comparing the number of cell divisions needed 426 
to accumulate the observed mutation counts with tumor size indicates a high rate of tumor cell 427 
death, so that only a minor fraction of cell divisions supports tumor growth. Therefore, it is 428 
plausible that the tumor remains of undetectable or barely detectable size for several years. To 429 
grow above the detection limit of current imaging techniques (about a millimeter in diameter), the 430 
tumor may need to acquire further mutations that stabilize cell survival. Activating TERT promoter 431 
mutations are a paradigmatic example of such mutations (Chiba et al., 2017), and our finding of 432 
subclonality of TERT promoter mutations in a sizeable fraction of tumors is consistent with the 433 
acquisition of this mutation in the process of tumor evolution.  434 
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Figure legends 701 
 702 
Figure 1. Clinical data and mutation statistics. See also Figure S1. 703 
(A) Sampling strategy.  704 
(B) Overview of clinical parameters and sequencing approaches (see also Figure S1).  705 
(C) Number of SNVs and small insertions/deletions called in primary and recurrent samples of the 706 
discovery set (red lines, median; red dots, hypermutated cases).  707 
(D) Numbers of common and private SNVs and small insertions/deletions of the discovery set (red 708 
lines, median; red dots, hypermutated cases).  709 
(E) Relative numbers corresponding to (D) per tumor.  710 
(F-H) Mutational signatures of shared (F) and private SNVs (G) from non-hypermutated cases of the 711 
discovery set, as well as mutational signatures of hypermutated cases (H). Data are represented as 712 
mean ± SEM. 713 
 714 
Figure 2. Recurrent driver mutations in paired primary and recurrent tumor samples from 21 715 
glioblastoma patients. See also Figure S2.  716 
(A) Mutational spectrum in likely driver genes. Coding genes are shown if targeted by a structural 717 
variation, SNV, indel, homozygous deletion or a high-level amplification in at least two patients 718 
(excluding hypermutated samples; mutations in MSH6 are additionally shown due to their 719 
correlation with a hypermutation genotype). Non-coding genes are shown if targeted by a SNV or 720 
an insertion/deletion in more than five patients. TERT promoter mutations are shown at the 721 
bottom. Primary and recurrent samples of a tumor are shown in pairs and separated by vertical 722 
lines (left primary, right secondary). Different colors mark different types of mutations while the 723 
color code at the bottom indicates DNA methylation subtypes.  724 
(B) Chromosomal gains and losses in primary and relapsed tumors.  725 
(C) Inter-chromosomal and intra-chromosomal structural variants in primary and relapsed tumors. 726 
Translocation partners are marked if targeting a gene or the vicinity of a super-enhancer (based on 727 
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dbSUPER; Khan et al., 2016). Genes targeted by intra-chromosomal variants are highlighted if they 728 
were present in the driver genes list. Numbers in brackets indicate the number of recurrences of a 729 
structural variant (tr., inter-chromosomal translocation; ic., intra-chromosomal variant).  730 
(D, E) Two examples of ongoing evolution on chromosome 7. Both cases can be explained by an 731 
initial gain of the chromosome, followed by partial losses in the recurrent (D) or the primary tumor 732 
(E) (black, normal copy number; green, gains; red, losses; light blue lines, number of A- and B-733 
alleles). 734 
 735 
Figure 3. Phylogenetic inference. See also Figures S3 and S4. 736 
(A) Variant allele frequencies at loci with normal copy numbers (excluding hypermutated samples 737 
and, for clarity, showing mutations in functional regions only). Clonal and subclonal mutations 738 
were classified based on a binomial test for clonality (significance level α = 0.05).  739 
(B) Principle of phylogenetic inference from whole-genome sequencing data, with fractions of 740 
mutated and reference reads at mutated loci (left panel), the inferred subclonal distribution 741 
(middle panel) and the resulting phylogenetic tree (right panel). The mutated DNA fraction within 742 
tumor subclones is indicated by a darker shading; stars mark examples of loci with copy number 743 
changes. The data shown are for the two subclones of the recurrent tumor in (H).  744 
(C, D) Summary statistics on inferred phylogenies, with number of subclones (C) and their relative 745 
sizes (D).  746 
(E) Layout of phylogenetic trees. Vertical branch lengths scale with the number of mutations, circle 747 
areas scale with relative subclone sizes. 748 
(F,G) Examples of phylogenetic trees with oligoclonal origin of the recurrent tumor, with (F) and 749 
without (G) recurrent driver mutations acquired after primary resection (yellow, primary tumor; 750 
orange, recurrent tumor; blue branches, common stem; grey branches, mutations originating in 751 
primary tumor; green branches, mutations found only in relapse tumor; asterisk marks convergent 752 
evolution; mutations in driver genes and copy number changes of chromosomes 7, 9 and 10 are 753 
indicated).  754 
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(H) Monoclonal origin of the recurrent tumor; primary and recurrent tumors are separated by a 755 
long branch and several new driver mutations (mutations in driver genes and copy number 756 
changes of chromosomes 7, 9 and 10 are indicated). 757 
(I) Origin of the recurrent tumor relative to origin of the primary tumor (excluding hypermutated 758 
cases). The distance between the most recent common ancestors (MRCA) of primary and recurrent 759 
samples (measured in mutation counts) is provided as a measure for tumor origin. 760 
(K) Consensus tree of all sample pairs. Branch widths and font sizes scale with the number of cases 761 
supporting a connection and mutation, respectively. The median number of clonal mutations and 762 
the median of the maximal number of mutations per subclone are indicated for primary and 763 
recurrent tumors. Driver mutations are indicated at particular tree branches [distinguishing clonal, 764 
subclonal, present in primary or recurrence only] if they are found there in at least two tumors and 765 
are frequent overall [present at any position in at least three (coding genes) or five (non-coding 766 
genes) non-hypermutated tumors].  767 
All data are from the discovery set subjected to deep WGS. 768 
 769 
Figure 4. Patterns of mutations during different stages of tumorigenesis. See also Figure S5. 770 
(A) Number of clonal and subclonal copy number changes on Chr. 7, 9 and 10. 771 
(B) Number of clonal and subclonal mutations (SNVs and indels) in driver genes that were clonal in 772 
at least one tumor. Red bars represent the numbers of tumors harboring at least one of the listed 773 
driver mutations clonally. In a few cases, mutations could not unambiguously be placed on the 774 
phylogenetic trees as clonal or subclonal; these were counted as clonal when the probability of 775 
placing them in the tumor stem was >10%. 776 
(C) Canonical (red) and non-canonical mutations (grey) in the TERT promoter region.  777 
All data are from the discovery set subjected to deep WGS. 778 
 779 
Figure 5. Evolutionary dynamics during glioblastoma growth. See also Figure S5.  780 
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(A) Model of tumor growth. Cells divide at rate λ, die at rate δ and accumulate mutations at rate λµ. 781 
Clinically detectable tumors have cell counts in the order of 109-1010, each of which on average 782 
accumulated 2300 mutations between tumor initiation and clinical detection (median of 17 non-783 
hypermutated tumors). 784 
(B) Schematic of the mutation counts used for rate estimation. Tumors are initiated by a somatic 785 
cell with M1 prior (neutral) mutations. Extant subclonal diversification occurs after MC mutations 786 
(i.e., at the most recent common ancestor of the tumor). Individual cells accumulate additional 787 
mutations during tumor growth (resulting in a total of M mutations per cell at clinical 788 
presentation).  789 
(C) The numbers of cell divisions and mutations scale logarithmically with the number of tumor 790 
cells. The slope of the growth curve is determined by the rate of cell death. Hence knowledge of 791 
tumor cell number and number of cell divisions allows to infer the rate of cell death. 792 
(D) Model for the acquisition of canonical TERT promoter mutations during glioblastoma evolution. 793 
A transformed cell divides due to initial pro-proliferative mutations (including the common CNVs in 794 
the tumor stem). After capturing an additional TERT promoter mutation with probability µ dt, the 795 
cellular death rate is reduced to δTERT. 796 
(E) Inferred and modeled cumulative distribution of the tumor fraction with canonical TERT 797 
promoter mutation (estimated from its most likely position in the phylogenetic trees of the 19 798 
cases with canonical TERT promoter mutation).  799 
(F) Model of glioblastoma growth (individual subclones are labeled by different shades of yellow to 800 
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STAR Methods 806 
 807 
CONTACT FOR REAGENT AND RESOURCE SHARING 808 
Further information and requests for resources and reagents should be directed to and will be 809 
fulfilled by the Lead Contact, Peter Lichter (peter.lichter@dkfz.de).  810 
 811 
EXPERIMENTAL MODEL AND SUBJECT DETAILS  812 
Patients and tissue samples  813 
We collected matched tissue samples from the initial surgery before treatment and a second 814 
surgery for recurrent tumor growth from 50 patients with IDHWT glioblastoma, World Health 815 
Organization (WHO) grade IV. The patients were identified in the central database of the German 816 
Glioma Network (GGN) or the database of the Central Nervous System (CNS) tumor tissue bank at 817 
the Department of Neuropathology, Heinrich Heine University, Düsseldorf, Germany. The GGN is a 818 
prospective, non-interventional cohort study involving eight clinical centers at University Hospitals 819 
in Germany (www.gliomnetzwerk.de), and was supported by the German Cancer Aid from 2004 to 820 
2012. Patients provided their written informed consent for participating in the GGN and the use of 821 
their tissue samples and clinical data for research purposes according to the research proposals 822 
approved by the Institutional Review Boards of the participating institutions. The present study 823 
was approved by the institutional review board of the Medical Faculty, Heinrich Heine University, 824 
Düsseldorf, Germany (study number 4940). Histology of all tumors was centrally reviewed and 825 
confirmed to correspond to glioblastoma, IDHWT, World Health Organization (WHO) grade IV 826 
according to the WHO classification of central nervous system tumors 2016 (Louis et al., 2016). All 827 
tissue specimens used in the present study for extraction of nucleic acids and molecular analyses 828 
were histologically evaluated to assure that they consisted of vital tumor tissue. Tissue samples 829 
corresponding mostly to necrosis or reactive changes were excluded. Relevant clinical data 830 
retrieved for each patient included information on age at diagnosis, gender, tumor location, extent 831 
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of resection, postoperative therapy, interval between primary and secondary surgery, and overall 832 
survival. Table S1 shows a summary of the respective patient data. 833 
 834 
METHOD DETAILS 835 
 836 
Immunohistochemical stainings 837 
Immunohistochemical stainings for ATRX (alpha-thalassemia/mental retardation syndrome, X-838 
linked) protein expression were performed on representative formalin-fixed and paraffin-839 
embedded tissue sections from selected cases of primary and recurrent tumors using an 840 
automated immunostainer (Dako, Kopenhagen, Denmark) and the UltraVisionTM Quanto 841 
horseradish peroxidase detection system with 3,3'-diaminobenzidine tetrahydrochloride as 842 
chromogen (Thermo Fisher Scientific, Freemont, CA). Sections were pretreated by heating them in 843 
retrieval solution (Dako) at pH 9.0 for 20 min. As primary anti-ATRX antibody, we used the mouse 844 
monoclonal IgG1 clone AX1 diluted 1:200 as recommended by the manufacturer (Dianova, 845 
Hamburg, Germany). All immunohistochemical sections were counterstained with hematoxylin. 846 
 847 
Extraction of DNA and RNA 848 
DNA was extracted from deep-frozen tumor tissue samples from 35 patients, including all patients 849 
whose tissue samples were subjected to WGS with the JETQUICK Tissue DNA Spin Kit (Genomed, 850 
Loehne, Germany). Extraction of constitutional (leukocyte) DNA from frozen peripheral blood 851 
samples was performed with the Pure Link Genomic DNA Mini Kit (Invitrogen, Carlsbad, CA). The 852 
RNeasy Mini Kit (Qiagen, Hilden, Germany) was used for extraction of total RNA from deep-frozen 853 
tissue samples. The GeneRead DNA FFPE Kit (Qiagen) was used for DNA extraction from formalin-854 
fixed and paraffin-embedded (FFPE) samples of 15 patients whose tumor samples were subjected 855 
to panel sequencing. All nucleic acid extractions were carried out according to the respective kit 856 
manufacturer’s protocol. Quality of extracted DNA was assured by spectrophotometric analysis and 857 
agarose gel electrophoresis. RNA quality was determined on an Agilent 2100 Bioanalyzer (Agilent 858 
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Technologies, Santa Clara, CA). Only samples showing a RNA integrity number (RIN) of 6.5 or more 859 
were used for RNA sequencing. 860 
 861 
DNA and RNA library preparation 862 
DNA libraries were prepared according to the Illumina TruSeq Nano DNA Library protocol using the 863 
TruSeq DNA Nano kit (Illumina, Hayward, CA) and sequenced on HiSeq X using the HiSeq X Ten 864 
Reagent Kit v2.5 (both Illumina, Hayward, CA). Total, strand-specific RNA libraries were prepared 865 
according to the Illumina TruSeq Stranded Total RNA Sample Preparation Guide (Illumina, 866 
Hayward, CA), with Ribo Zero Gold (Epicentre, Madison, WI) depletion of rRNA. 867 
 868 
Gene panel next generation sequencing 869 
In total, we analyzed pairs of primary and recurrent IDHWT glioblastomas from 43 patients (including 870 
14 of the 21 patients whose tumors were analyzed by whole genome sequencing) using next 871 
generation sequencing of a gene panel covering 50 selected genes. Libraries for gene panel 872 
sequencing were prepared using the Ion AmpliSeq™ Library 2.0 Kit (Life Technologies, Carlsbad, 873 
CA, USA) and two customized AmpliSeqTM gene panels. Gene panel 1 has been published 874 
elsewhere (Zacher et al., 2017) and covers the complete coding sequences (cds) or selected 875 
genomic regions including mutation hot spots (region) of the following 20 genes: NRAS (cds), 876 
FUBP1 (cds), CDKN2C (cds), H3F3A (region), IDH1 (region), PIK3CA (cds), TERT (region), PIK3R1 (cds), 877 
EGFR (cds), BRAF (region), CDKN2A (cds), CDKN2B (cds), PTEN (cds), RB1 (cds), IDH2 (region), TP53 878 
(cds), NF1 (cds), CIC (cds), NF2 (cds) and ATRX (cds). Gene panel 2 covers complete cds or regions 879 
including mutation hot spots of the following 30 genes: MDM4 (region), PIK3C2B (cds), ACVR1 880 
(region), MSH6 (cds), MSH2 (cds), RAB7A (region), MLH1 (cds), PDGFRA (cds), MYB (region), CCND3 881 
(region), DAXX (cds), HIST1H3B (cds), CDK6 (region), MET (region), PMS2 (cds), MYBL1 (region), FGFR1 882 
(region), NTRK2 (cds), TSC1 (cds), MTAP (cds), CCND1 (region), CDK4 (region), PTPN11 (cds), MDM2 883 
(region), CCND2 (region), KRAS (cds), IRS2 (region), GABRG3 (region), TSC2 (cds) and PPM1D (cds). 884 
Library preparation for gene panel sequencing was carried out according to the manufacturer’s 885 
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protocol (Zacher et al., 2017) (MAN 006735 Rev 5.0, Life Technologies).  A total of four primer pools 886 
were PCR amplified using 10 ng of genomic DNA per primer pool as template. Emulsion PCR and 887 
enrichment was carried out on the Ion OneTouch™ 2 System using the Ion PI™ Template OT2 200 888 
Kit v3 (MAN0009133 Rev A, Life Technologies). The Ion ProtonTM System (Life Technologies) was 889 
used for sequencing using the Ion PI™v2 chips and the Ion PI™ 200 Sequencing 200 Kit v3 890 
(MAN0009136 Rev.A, Life Technologies). Overall, at least 1 million reads were generated per library. 891 
Data analysis was performed with the Torrent SuiteTM software 4.4 employing the implemented 892 
TMAP algorithm (Life Technologies). Variants were detected using the VariantCaller Plugin v4.4 and 893 
the predefined parameter set ‘somatic high stringency’ (Life Technologies, for detailed annotation 894 
information see Zacher et al., 2017). The Integrative Genomics Viewer (IGV) software was used to 895 
visualize the read alignment and check for possible errors. Copy number variations were identified 896 
with the NextGENe® v.2.3.4 software (SoftGenetics, State College, PA).  897 
 898 
Alignment of whole genome sequencing reads 899 
Read pairs were mapped to the human reference genome (build 37, version hs37d5) using bwa 900 
mem (Li and Durbin, 2009) (version 0.7.8, with minimum base quality threshold zero [-T 0] and 901 
remaining settings left at default values), followed by coordinate-sorting with bamsort (with 902 
compression option set to fast (1)) and marking duplicate read pairs with bammarkduplicates (with 903 
compression option set to (9)); both are part of biobambam (Tischler and Leonard, 2014) package 904 
version 0.0.148.   905 
 906 
Detection of SNVs and indels 907 
Somatic SNVs and indels in matched tumor normal pairs were identified using the DKFZ core 908 
variant calling workflows of the ICGC PCAWG project 909 
(https://dockstore.org/containers/quay.io/pancancer/pcawg-dkfz-workflow). Briefly, in the DKFZ 910 
SNV pipeline candidate SNV calls were generated by samtools (Li et al., 2009) and bcftools (version 911 
0.1.19), and potential variants called in the tumor were followed by a lookup of the corresponding 912 
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positions in the control. To enable calling of variants with low allele frequency we disabled the 913 
Bayesian model (by setting -p 2). Thus, all positions containing at least one high quality non-914 
reference base are reported as candidate variant. The resulting raw calls were categorized into 915 
putative somatic variants and others (artifacts, germline) based on the presence of variant reads in 916 
the matched normal sample. The frequency of all putative somatic variants was then refined by 917 
checking for potential redundant information due to overlapping reads, and precise base counts 918 
for each strand were determined. All variants were annotated with dbSNP141, 1000 Genomes 919 
(phase 1), Gencode Mapability track, UCSC High Seq Depth track, UCSC Simple-Tandemrepeats, 920 
UCSC Repeat-Masker, DUKE-Excluded, DAC-Blacklist, UCSC Selfchain. The confidence for each 921 
variant was then determined by a heuristic scoring scheme taking the aforementioned tracks into 922 
account. In addition, variants with strong read biases which fell into a bias-prone context according 923 
to the strand bias filter were removed. High confidence variants (confidence score 8-10) were 924 
reported. For indel calling, Platypus (Rimmer et al., 2014) version 0.7.4 was used.  All candidate 925 
indel variants were categorized into putative somatic and other based on the genotype likelihoods 926 
(matched genotype 0/0 for somatic indels). High confidence somatic variants were required to 927 
either have the Platypus filter flag PASS or pass custom filters allowing for low variant frequency 928 
using a scoring scheme. Candidates with the badReads flag, alleleBias, or strandBias were 929 
discarded if the variant allele frequency was <10%. Additionally, combinations of Platypus non-930 
PASS filter flags, bad quality values, low genotype quality, very low variant counts in the tumor, and 931 
presence of variant reads in the control were not tolerated. SNVs and indels were annotated using 932 
ANNOVAR (Wang et al., 2010) according to GENCODE gene annotation (version 19) and overlapped 933 
with variants from dbSNP (Sherry et al., 2001) (build 141) and the 1000 Genomes Project database. 934 
  935 
Detection of structural variants (SVs) 936 
Genomic structural rearrangements were detected using SOPHIA v.34. Briefly, SOPHIA uses 937 
supplementary alignments as produced by bwa mem as indicators of a possible underlying SV. SV 938 
candidates are filtered by comparing them to a background control set of sequencing data 939 
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(obtained using normal blood samples from a background population database of 3261 patients 940 
from published TCGA and ICGC studies and both published and unpublished DKFZ studies, 941 
sequenced using Illumina HiSeq 2000, 2500 (100 bp) and HiSeq X (151 bp) platforms and aligned 942 
uniformly using the same workflow as in this study). An SV candidate is discarded if (i) it has more 943 
than 85% of read support from low quality reads; (ii) the second breakpoint of the SV was 944 
unmappable in the sample and the first breakpoint was detected in 10 or more background control 945 
samples; (iii) an SV with two identified breakpoints had one breakpoint present in at least 98 946 
control samples (3% of the control samples); or (iv) both breakpoints have less than 5% read 947 
support. SVs were annotated as somatic if the respective event had no support in the matched 948 
normal sample. 949 
 950 
Detection of copy number aberrations  951 
Allele-specific copy-number aberrations were detected using ACEseq (allele-specific copy-number 952 
estimation from whole genome sequencing) (Kleinheinz et al., 2017). ACEseq determines absolute 953 
allele-specific copy numbers as well as tumor ploidy and tumor cell content based on coverage 954 
ratios of tumor and control as well as the B-allele frequency (BAF) of heterozygous single 955 
nucleotide polymorphisms (SNPs). SVs called by SOPHIA were incorporated to improve genome 956 
segmentation. The estimated tumor cell content was compared to the doubled median of the 957 
somatic SNV mutation allele frequency distribution and adjusted if the estimates deviated by more 958 
than 10% from each other. Genomic segments were annotated as losses if their total copy number 959 
(TCN) was smaller than the sample’s ploidy by at least 0.3. Segments with an estimated TCN < 0.5 960 
were annotated as homozygous deletions. Analogous to losses, gains were identified as segments 961 
with ploidy – TCN < -0.3. High level amplifications were classified as segments with TCN > 2.5 x 962 
ploidy. Loss of heterozygosity was defined as segments with the copy number of the minor allele < 963 
0.3.  964 
 965 
Alignment and counting of RNA sequencing reads 966 
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Sequencing reads were aligned to the human genome (hg19 build) with the Gencode reference 967 
transcriptome (v19) using STAR (v2.3.0e) (Dobin et al., 2013). Read counts for each gene were 968 
determined as the total number of reads mapping to exons using htseq-count (0.6.0) (Anders et al., 969 
2015) and the GENCODE transcript model (v19).  970 
 971 
450k/EPIC methylation arrays 972 
DNA methylation profiling was performed by using 450k or EPIC methylation bead arrays (Illumina, 973 
Hayward, CA) according to standard protocols. Data were processed and analysed as reported 974 
elsewhere (Capper et al., 2018). 975 
 976 
Signature analysis 977 
Supervised mutational signature analysis was performed with the R package YAPSA 978 
(Huebschmann et al., 2015). Using the function LCD_complex_cutoff(), we computed a non-979 
negative least squares (NNLS) decomposition of the mutational catalogue with 30 known 980 
signatures from COSMIC (http://cancer.sanger.ac.uk/cosmic/signatures)). In order to increase 981 
specificity, LCD_complex_cutoff() applies the NNLS algorithm twice. A first NNLS is run proposing 982 
all supplied signatures to the decomposition, then a second NNLS is run again with a reduced set 983 
of signatures consisting only of those signatures whose exposures were higher than a certain 984 
signature-specific cutoff. The signature-specific cutoffs were determined in a random operator 985 
characteristic (ROC) analysis using publicly available data on mutational catalogues of 7,042 cancer 986 
samples (507 from whole genome sequencing and 6,535 from whole exome sequencing; 987 
Alexandrov et al., 2013) and mutational signatures (http://cancer.sanger.ac.uk/cosmic/signatures, 988 
downloaded on January 15th, 2016). The following cut-offs were employed - AC1: 0; AC2: 989 
0.03193533; AC3 0.1082812; AC4: 0.03266562; AC5: 0; AC6: 0.003351944; AC7: 0.0280924; AC8: 990 
0.1814745; AC9: 0.09121354; AC10: 0.01686839; AC11: 0.07757047; AC12: 0.1937234; AC13: 991 
0.01665886; AC14: 0.03158583; AC15: 0.03138468; AC16: 0.3521707; AC17: 0.004232865; AC18: 992 
0.236441; AC19: 0.04058829; AC20: 0.04701714; AC21: 0.04009243; AC22: 0.03756267; AC23: 993 
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0.04005552; AC24: 0.03503163; AC25: 0.01658311; AC26: 0.0261603; AC27: 0.02200583; AC28: 994 
0.03145322; AC29: 0.07188295; AC30: 0.03147694. This analysis was performed separately for 995 
hypermutated and non-hypermutated tumors. To identify signature enrichment and depletion 996 
patterns between shared and private, as well as between clonal and subclonal SNVs, a stratified 997 
signature analysis was performed using the function run_SMC() from YAPSA as described in 998 
Giessler et al, 2017. Briefly, the stratified analysis was performed as a multistep procedure: (1) a 999 
supervised analysis of mutational signatures was run without any stratification; (2) for every SNV in 1000 
a sample, the stratum it belonged to was annotated; (3) for every stratum, a stratum-specific 1001 
mutational catalog was built; and (4) a supervised NNLS (using lsei) with the constraint that the 1002 
sum of exposures per stratum equals the exposures computed by the unstratified analysis was 1003 
performed. Thereafter, enrichment and depletion patterns for all mutational signatures detected in 1004 
step 1 were computed (Kruskal Wallis tests followed by pairwise posthoc Nemenyi tests corrected 1005 
for multiple testing according to Benjamini and Hochberg (BH)) from the exposures in all strata 1006 
with the help of the function stat_test_SMC(). 1007 
 1008 
Estimation of cell type composition  1009 
The enrichment of different cell types in tumor samples was evaluated from gene expression and 1010 
DNA methylation data. Gene expression data were analyzed using the R package MCP-counter 1011 
(Becht et al., 2016) on normalized read counts (logarithmic reads per kilobase per million). MCP-1012 
counter quantifies the abundance of eight immune cell populations, endothelial cells and 1013 
fibroblasts from transcriptomic markers unique to either of the cell types. For each cell type a score 1014 
is computed using the log2 geometric mean of the corresponding markers. Signatures of neural 1015 
and blood cells in DNA methylation data were deconvolved using the function 1016 
estimateCellCounts() implemented in the R packages minfi (Aryee et al., 2014). The function uses 1017 
regression calibration to estimate the proportions of NeuN+ and NeuN- cells 1018 
(FlowSorted.DLPFC.450k; Jaffe et al., 2018) and of different blood cells (FlowSorted.Blood.450k; 1019 
Jaffe et al., 2018) from 450k/EPIC methylation data. 1020 
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 1021 
Driver gene selection 1022 
Putative driver mutations in glioblastoma were called based on the public database Intogen 1023 
(Rubio-Perez et al., 2015; Gonzalez-Perez et al., 2013) and from recurrence. Among coding genes 1024 
we searched for overrepresentation launching OncodriveFML (Mularoni et al., 2016) (with the 1025 
coding regions file taken from https://bitbucket.org/bbglab/oncodrivefml/downloads/) and 1026 
accepted genes at q-values ≤ 0.1 (Benjamini-Hochberg-corrected). We included non-coding genes 1027 
if they were mutated in more than five patients. We in addition included TERT promoter mutations 1028 
as likely drivers (Barthel et al., 2018), considering the region up to 2,500 base pairs upstream of the 1029 
transcription start site. 1030 
 1031 
Subclonality test 1032 
To determine subclonality in Figure 3A we modeled mutation counts as a sampling result from a 1033 
binomial distribution. If sampling from a diploid locus, the sampling probability of a clonal 1034 
mutation is 0.5xCCF, where CCF denotes the cancer cell fraction. We determined CCF during 1035 
phylogenetic inference as described in detail below. Loci of different copy number states shift the 1036 
sampling probability non-trivially. We excluded these loci, requiring a (normalized) coverage ratio 1037 
between 0.9 and 1.1, and in addition excluded mutations on male sex chromosomes. Subclonality 1038 
was then assumed if the measured mutation counts fell below the 95%-quantile of a binomial 1039 
distribution with sampling probability 0.5xCCF, i.e. 1040 
   (1) 1041 
where rref and rmut denote the measured reference and mutated reads of a SNV or small 1042 
insertion/deletion. In case of loss of heterozygosity, equation (1) is modified to 1043 
   (2) 1044 
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We then used the classified mutations to estimate the number of subclonal mutations that appear 1045 
clonal in a tumor sample due to incomplete tissue sampling. The fraction of these false positive 1046 
clonal mutations can be assessed from mutations which were clonal in the primary and subclonal 1047 
in the relapse sample. In fact, these mutations must have already been subclonal in the primary 1048 
tumor as a transition from clonality to subclonality violates a single tumor origin. The false positive 1049 
rate of clonal mutations due to incomplete tumor sampling thus reads  1050 
  , (3) 1051 
where ncPsR is the number of mutations which were clonal in the primary and subclonal in the 1052 
relapse sample and ncPcR is the number of mutations which were clonal in both samples. 1053 
 1054 
Phylogenetic inference 1055 
General considerations 1056 
Our phylogenetic analysis aims at inferring genetic subclones in pairs of primary and relapse 1057 
tumors that are characterized by a combination of oncogenic drivers (encompassing mutations 1058 
and copy number variations). Thus we will deduce robust features of the evolving phylogenetic 1059 
tree of a tumor, including which driver mutations are in the common stem (i.e., occurred 1060 
comparatively early) and which mutations are still subclonal at the times of surgical resection (and 1061 
hence occurred later). Moreover, we will infer the common origins of subclones in the primary and 1062 
relapse tumors, showing whether the relapse evolved from a unique subclone or multiple 1063 
subclones in the primary tumor. For this analysis, we include all somatic variants specific to the 1064 
tumor and do not restrict ourselves to known driver mutations. In particular, the majority of the 1065 
12,800 somatic SNVs recovered on average from a tumor are most likely neutral. However, the VAFs 1066 
of neutral mutations in a tumor cell that harbors specific oncogenic drivers will grow in a 1067 
coordinate manner as the subclone emerging from this cell expands, leading to many SNVs with 1068 
the same VAF. In turn, this feature will facilitate the detection of the subclone in bulk WGS data.  1069 
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The subclonal structure of a phylogenetic tree can be considered at different levels of 1070 
resolution, from major branching down to single cells. Too fine a resolution is not of interest here 1071 
because the vast majority of small subclones will be distinguished only by neutral somatic 1072 
mutations that contain no information on tumor evolution by acquisition of driver mutations. Also, 1073 
finely resolved phylogenetic trees cannot uniquely be reconstructed from bulk WGS data as 1074 
mutations with small VAFs cannot be mapped uniquely to a large number of small subclones. 1075 
These two considerations underscore our aim of reconstructing the occurrence of major drivers 1076 
during genetic tumor evolution, which also motivates model selection (see below) favoring 1077 
parsimonious trees that yield appropriate fits to the data. Importantly, the phylogenetic inference 1078 
does not make assumptions on why two or more subclones coexist; coexistence could be a 1079 
snapshot in the process of a newly evolved subclone outcompeting its predecessor(s) or be due to 1080 
cooperation of subclones.    1081 
Assuming monoclonal origin of the tumor and neglecting the (very small) probability of 1082 
backward evolution, a tumor can be visualized by a phylogenetic tree whose root corresponds to 1083 
the founder cell of the tumor and whose tips represent the subclones in the tumor sample (Figure 1084 
S3A). In accordance with the infinite sites hypothesis (Kimura, 1969), we assume that all SNVs and 1085 
small insertions/deletions are singular events in the phylogenetic tree. Copy number changes 1086 
often span larger regions so that the infinite sites model might not be adequate here, and a copy 1087 
number change measured in both tumor samples could also be due to independent events. We 1088 
address this by allowing up to two independent events changing copy number at a single locus, as 1089 
described below in detail. 1090 
 1091 
Mathematical description of the model 1092 
Assuming well-mixed samples, we model read counts in whole genome sequencing as a sampling 1093 
result from a multinomial distribution, whose different categories represent the genetic subclones 1094 
in the tumor. At each genomic locus the probability to sample reads from a distinct subclone scales 1095 
with its relative size and its copy number state. Let  denote the i-th subclone in a 1096 
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heterogeneous tumor with K subclones and  the proportion of cells in the sample 1097 
originating from each subclone. Then, at each locus l, the probability to sample a read from SC i in a 1098 
Bernoulli trial can be written as 1099 
   (4) 1100 
where  are integers that denote the copy numbers at locus l in each 1101 
subclone. Now, let s i = (s i,l, ..., sK,l|s i,l = {0, ..., π i,l}) be integers that denote the number of mutated 1102 
alleles at locus l in each subclone. Accordingly, the probabilities to sample a read supporting the 1103 
reference genome or a mutation, respectively, are given by 1104 
   (5) 1105 
In bulk sequencing, the genomes from all subclones are intermingled. Consequently, 1106 
rLref reference reads and r lmut mutated reads at locus l originate from the K subclones in the sample, 1107 
such that 1108 
   (6) 1109 
With this, the likelihood function for a measured number of reference and mutated reads at locus l 1110 
is given by 1111 
   (7) 1112 
with the corresponding log-likelihood, l l, 1113 
   (8) 1114 
where C is a constant that solely depends on the read counts. 1115 
 1116 
Solution space and phylogenetic tree design 1117 
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We assume that tumors evolve from a monoclonal origin and can be visualized by a phylogenetic 1118 
tree. This restricts the solution space for subclonal inference as we will see in the following. 1119 
Invoking the infinite sites hypothesis (Kimura, 1969), we require that the combinations of 1120 
subclones carrying a mutation can be explained by a single event in the tree and are present on 1121 
one of the two parental alleles only. We thus require 1122 
   (9) 1123 
where B l is the number of B-alleles at locus l.  1124 
If an SNV collocates with a CNV, s l becomes further restricted by the following criteria: 1125 
• if the copy number change precedes the mutation in the phylogenetic tree, the mutation 1126 
can only be present on one allele 1127 
• if the mutation precedes the copy number change, the mutation must either be present on 1128 
all A-alleles or on all B-alleles 1129 
• if the order of mutation and copy number change is unclear, the mutation can be present 1130 
on any number of A- or B-alleles. 1131 
 1132 
Model selection 1133 
To estimate µ, π and s, we first test a priori designed phylogenetic trees (Figure S3A). By treating 1134 
normal tissue as an additional subclone, this automatically accounts for sample purity. Note that 1135 
we designed the candidate trees in such a way that, in general, all subclones present in the primary 1136 
sample are different from the ones in the relapse sample. However, this also comprises solutions in 1137 
which the same subclone is present in both samples if the branches separating the two subclones 1138 
are collapsed (Figure S3B). Similarly, these trees can also be collapsed into topologies of linear 1139 
evolution (Figure S3B). 1140 
To select the most likely tree among the candidate topologies, we first require a good fit of 1141 
the tumor stem. This is achieved by discarding trees in which more than 50% of the clonal (truncal) 1142 
mutations are ambiguously mapped and, further, by discarding trees whose average squared error 1143 
of clonal variant allele frequencies (VAFs) lay outside the 10% quantile of all candidate trees. We 1144 
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then assess the likelihoods of the remaining trees with a modified Bayesian Information Criterion 1145 
(BIC) (Chen and Chen, 2008). Briefly, the modified BIC incorporates increasing model complexity 1146 
with increasing numbers of parameters: 1147 
   (10) 1148 
where n is the number of data points, v the number of parameters and τ a parameter accounting 1149 
for increasing model complexity weighted by ϒ. In our case the number of data points is the 1150 
number of readcounts (r lref +r lmut), the number of parameters is the number of subclones, K, and τ is 1151 
obtained by summing up all possible values of s. We choose ϒ = 0.9 to stringently incorporate the 1152 
increasing model complexity when increasing the number of parameters. 1153 
We fit all 96 trees consisting of up to three tumor subclones per sample (Figure S3A) and 1154 
identified the most likely solutions based on the reliability of the estimated clonal mutations and 1155 
the modified BIC, as explained above.  1156 
 1157 
Parameter estimation 1158 
Parameter estimations were performed on 500 mutated loci (including coding mutations and filled 1159 
up by randomly chosen non-coding mutations). Subsequently, all mutations were mapped on the 1160 
inferred tree structure. Upon fitting, copy number variations were manually inspected to identify 1161 
large gains/losses and to adjust the solution in the case of inference problems due to high level 1162 
amplifications or homozygous deletions.  1163 
We jointly estimated the parameters of matched primary and relapse samples with a 1164 
maximum likelihood approach based on an expectation-maximization algorithm for different 1165 
candidate trees. At a given evolutionary tree, a nested expectation step is followed by likelihood 1166 
maximization from which the new input to the expectation step is generated. Both steps were 1167 
iteratively repeated until convergence (required as  where i is the index 1168 
of the iteration). In order to identify the global maximum, optimization was repeated 100 times at 1169 
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random starting conditions for each candidate tree. Expectation and maximization steps are 1170 
described in detail in the following. 1171 
 1172 
Expectation 1173 
We initiated the algorithm with randomly chosen values for μ. In all following iterations, the 1174 
parameter estimates obtained in the maximization step were given as input. In each expectation 1175 
step, the expected counts of mutated and reference reads per subclone were iteratively calculated 1176 
at each mutated locus after inferring the copy number state as follows: 1177 
Expectation step: copy numbers  1178 
We assume that there is at most one dominating copy number change, CNaberr,l, per locus and 1179 
sample. This change does not have to be present in all subclones, allowing for tumor 1180 
heterogeneity. While we allow different copy number changes to dominate the primary and the 1181 
relapse sample at a specific locus, we do not allow for multiple copy number changes per locus 1182 
within a sample. 1183 
We determined CNaberr,l from the normalized coverage ratios between tumor and blood along 1184 
with the measured B-allele frequencies, BAF l, in the tumor. To this end, we applied the following 1185 
criteria: 1186 
• If no information on the coverage ratio was available, we assumed normal ploidy (2 on 1187 
autosomes and female sex chromosomes, 1 on male sex chromosomes). If no information 1188 
on the B-allele frequency was available, we assumed a B-allele frequency of 0.5 on 1189 
autosomes and female sex chromosomes and of 0 on male sex chromosomes. 1190 
• We assumed that loci with coverage ratios in the interval [0.9, 1.1] and a BAF in the interval 1191 
[0.45, 0.55] (or [0, 0.05] in case of male sex chromosomes) reflect normal copy number 1192 
states, CNnorm, such that CNaberr,l = CNnorm = 2 on autosomes and female sex chromosomes 1193 
and CNaberr, l = CNnorm = 1 on male sex chromosomes. The cutoffs were chosen based on the 1194 
expected standard deviation of 8 % in Poisson distributed read counts at a coverage of 1195 
150x. 1196 
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• At all other loci, we inferred the copy numbers and B-allele numbers by minimizing the 1197 
squared errors between the expected and observed coverage ratios and B-allele 1198 
frequencies. To this end, we started with a single copy number, which we iteratively 1199 
increased. At each copy number we then tested different subclonal distributions   of 1200 
the copy number change, where f is a vector f = (f1, f2, . . . , fK), whose elements are binary 1201 
indicators of a copy number change in the respective subclone, i.e. . The different 1202 
combinations are restricted by the candidate tree and comprise solutions in which the 1203 
same or two different copy number changes dominate the primary and the relapse sample, 1204 
respectively. We computed the expected B-allele frequency for B-allele counts, Baberr,l, in the 1205 
interval [0, CNaberr,l] 1206 
   (11) 1207 
and chose the B-allele count that minimized the squared error between expected and 1208 
observed B-allele frequencies. Likewise, we computed the expected coverage ratio, E[cr l], 1209 
with 1210 
   (12) 1211 
We aborted the algorithm once (E[BAF l] - BAF l,obs)2 + (E[cr l] - cr l,obs)2 < 0.01 (the threshold of 1212 
0.01 corresponds to the expected Poisson noise at sequencing depths of 150x) and 1213 
determined B i,l and π i,l for each  to 1214 
   (13) 1215 
Note that while here only the most likely intratumoral distribution of a CNVs is selected, we 1216 




Expectation step: SNVs and small indels 1220 
Having inferred the copy number state at locus l we determined the expected read counts 1221 
for each possible combination of s l and π l  (which are predefined by the candidate tree) with 1222 
   (14) 1223 
where p’ i,lref and p’ i,lmut are the conditional probabilities of a sampled reference or mutated 1224 
read originating from SC i provided that µ, s and π are known. We then computed the 1225 
corresponding likelihood of µ, s and π as 1226 
   (15) 1227 
and selected the solution with the highest likelihood (note that we considered alternative solutions 1228 
for data representation and analysis also, if the best solution accounted for less than 90% of the 1229 
total likelihood). Since DNA is fragmented before amplification and mapping, the read count 1230 
distributions at different loci are independent of each other, so that the expectation step can be 1231 
independently evaluated at each mutated locus. Of note, independence of measured coverage 1232 
ratios is not guaranteed, since copy number variations can span multiple loci. This is already 1233 
accounted for during segmentation and, thus, does not affect the inference procedure. 1234 
 1235 
Maximization 1236 
We maximized the log-likelihood function (eqn. 8) at the expected readcount distribution 1237 
(eqn. 14) w.r.t. µ. This was approached by summing up the log-likelihoods (eqn. 1238 
8) at each locus and by introducing the constraint  with a Lagrange multiplier before 1239 
maximization: 1240 
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   (16) 1241 
After inserting equation 5 into equation 16, deviation with respect to µ i and λ yields: 1242 
   (17) 1243 
   (18) 1244 
We find the maximum of the log-likelihood by setting equations (17) and (18) equal 1245 
to zero and solving for λ and μ: 1246 
   (19) 1247 
   (20) 1248 
Summing up eqn. 19 over all subclones yields 1249 
   (21) 1250 
With equation 20 this reduces to 1251 
   (22) 1252 
and consequently, by inserting equation 22 into equation 19, μ i can be determined as 1253 
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   (23) 1254 
which reduces to 1255 
   (24) 1256 
 1257 
Ambiguous solutions 1258 
To avoid bias in data interpretation due to ambiguous solutions, we accounted for three types of 1259 
ambiguity: 1260 
• CNVs. If model inference suggested two independent copy number changes in primary 1261 
and relapse tumor, respectively, but the squared error of a joined solution was less than 1262 
twice the least squared error, we accounted for the joined solution in data analysis and 1263 
interpretation. Likewise, if the squared error for a clonal copy number change was less than 1264 
twice the error of a subclonal copy number change, we accounted for the clonal solution.  1265 
• SNVs. If the location of a mutation to the phylogenetic tree was non-unique, i.e., if the best 1266 
solution carried less than 90% of the total likelihood at this locus, we sorted solutions by 1267 
decreasing likelihood and accounted for all solutions that jointly yielded at least 90% of the 1268 
total likelihood in data analysis and interpretation. 1269 
• Tree structure. We accounted for all solutions with BICϒ ≤ min(BICϒ) + 10. 1270 
 1271 
Simulated data 1272 
To test the performance of phylogenetic tree reconstruction against a known “ground truth” 1273 
computationally, we generated 100 test sets of up to three primary and recurrent subclones, 1274 
respectively, according to the following algorithm: 1275 
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• Sample between one and three primary and recurrent clones (Kprim and Krec) 1276 
• Sample the corresponding subclone sizes, μprim and μrec, at a minimal tumor cell content of 1277 
0.5 1278 
• Sample a random tree from Figure S3A 1279 
• Sample Kprim and Krec nodes from this tree 1280 
• Sample between 1 and 200 mutations per subclone 1281 
• For each mutation sample a copy number change, π l: 1282 
o Normal copy numbers (two alleles) are weighted 15-fold 1283 
o A unary copy number change (± 1) is weighted 2-fold 1284 
o Copy number changes of up to +8 are weighted 1-fold each 1285 
• From the tree structure, sample the subclones that carry the copy number change, stored 1286 
in the indicator vector π l 1287 
• At each copy number change sample whether the mutation was affected by the copy 1288 
number change; from this determine s l 1289 
• Simulate the coverage ratios according to1290 
 thus, adding Gaussian noise to the 1291 
simulated coverage ratios 1292 
• Sample the read depth per locus from a Poisson distribution with λ = 150, corresponding to 1293 
an average read depth of 150. Then, based on the read depth, sample the number of 1294 
mutated reads from a binomial distribution with sampling probabilities according to 1295 
equation (5). 1296 
 1297 
Modeling of clonal dynamics 1298 
To link genetic evolution and tumor growth, we considered a deterministic model of tumor 1299 
growth and mutation accumulation. We assumed exponential tumor growth at rate λ-δ, 1300 
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where λ denotes the rate of cell division and δ the rate of cell death. The number of tumor cells, N, 1301 
is modeled as 1302 
   (25) 1303 
We implemented mutation accumulation at a constant rate μ per cell division, so that the 1304 
number of mutations per cell, m, grows linearly with the number of divisions: 1305 
   (26) 1306 
Accordingly, the time it takes to accumulate m mutations in a tumor cell is 1307 
   (27) 1308 
Knowing μ, m(t) and the number of tumor cells, N(t), we can estimate the ratio between 1309 
cell death and division without information on the tumor age. Rewriting equation 25 and 1310 
inserting equation 27 yields: 1311 
   (28) 1312 
where we defined  as the death rate relative to cell divisions. To estimate  from our data, μ, m(t) 1313 
and N(t) were chosen as follows: 1314 
• We assumed a mutation rate between 0.26 x 10-8 to 1.06 x 10-8 mutations per cell division 1315 
(Milholland et al., 2017). The upper boundary corresponds to a four-fold increase in somatic 1316 
mutation rate, accounting for a drop in the proportion of the mutational signature 1 (linked 1317 
to cell divisions) between tumor stem and tips (Figure S5K). 1318 
• We conservatively estimated the number of mutations per tumor cell at diagnosis as the 1319 
average number of non-clonal mutations in all subclones of the primary tumor. Note that 1320 
the mutations present in a subclone are shared by all cells of the subclone and thus have 1321 
been accumulated in a single cell. 1322 
• Finally, we estimated a tumor size of approximately 109 - 1010 cells at diagnosis. This 1323 
estimate has previously been suggested as the number of tumor cells per cubic centimeter 1324 
(Del Monte, 2009; De Vita et al., 1975) and is in agreement with a brain tumor size of 20 - 80 1325 
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cm3 and 1012 glia cells per brain (Goldberg-Zimring et al., 2005, Herculaono-Houzel et al., 1326 
2006, Milo et al., 2010, Pakkenberg et al., 1997) (corresponding to a brain size of 1327 
approximately 1500 cm3, see Drachman et al., 2005). 1328 
 1329 
Selective advantage of TERT promoter mutations 1330 
To estimate the selective advantage provided by canonical TERT promoter mutations, we modeled 1331 
its random acquisition and subsequent clonal expansion. The model samples the time of 1332 
occurrence of the TERT promoter mutation from a Poisson process with given mutation rate. From 1333 
this point onward, the TERT promoter-mutant subclone grows faster than TERT promoter-wildtype 1334 
tumor cells. The model simulation is terminated when the tumor reaches the characteristic size of 1335 
surgical resection. At this end point, the TERT promoter-mutant subclone may have reached 1336 
clonality or may still be subclonal (although it would eventually become clonal if the tumor were 1337 
allowed to grow for another year or so). Repeating this simulation will therefore result in a 1338 
distribution for the TERT promoter-mutant tumor fraction that will be compared with the 1339 
experimental data. The free parameter in this model is the selective advantage conferred by the 1340 
TERT promoter mutation. This parameter will be adjusted such that the model matches the data, 1341 
thus providing an estimate of the selective advantage conferred by the TERT promoter mutation. 1342 
We began by assessing the probability of capturing the mutation after a certain number of 1343 
cell divisions. The probability of at least one mutation (denoted as TERT*) after ndiv divisions is given 1344 
by 1345 
   (29) 1346 
where μbp denotes the per base substitution rate per cell division. The mutation probability 1347 
is scaled by a factor of 2 accounting for the two canonical TERT promoter mutations recurrently 1348 
observed in glioblastoma (chr5, 1,295,228 C>T and 1,295,250 C>T). The number of divisions, ndiv is a 1349 
time dependent function, modeled by 1350 
   (30) 1351 
which, using equation 25 can be solved by 1352 
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   (31) 1353 
Inserting this into equation 29 we obtain the probability distribution of at least one TERT 1354 
promoter mutation at timepoint t. We modeled the effect of TERT promoter mutations by a 1355 
decrease in cell death since these mutations have been linked to increased cellular survival 1356 
(Chiba et al., 2017). Consequently, the expansion of the TERT mutated tumor fraction, 1357 
NTERT, is modeled by 1358 
   (32) 1359 
The expansion of the tumor founder population is modeled by equation 25. The total tumor size 1360 
consequently equals the sum of equations 25 and 32. Since TERT promoter mutations were found 1361 
clonally in ≥ 2/3 of the tumors, the estimated tumor cell death fraction,  (eqn. 1362 
28) must hold true for TERT mutated cells. Accordingly, we fixed the lower boundary of   1363 
based on equation 28 and for each   evaluated the death rate of the 1364 
founder population, . To do this we scanned the range  and at each value 1365 
sampled 1,000 instances of the timepoint of the TERT promoter mutation, T0,TERT, from equation 29 1366 
(assuming single base substitution rates of 0.26 x 10-8 to 1.06 x 10-8 (Milholland et al., 2017) and a 1367 
tumor size of 109 cells, as before). We then evaluated the goodness of fit at each parameter 1368 
combination by minimization, comparing the mean and variance of the simulated and 1369 
measured TERT mutated tumor fraction (the uncertainties of the mean and the variance in the 1370 
measurement were estimated using bootstrapping with 10,000 resampling steps). Parameter 1371 
combinations with , corresponding to the 95% confidence interval of the Chi2-1372 
distribution yield equally good fits and we selected the values of  from 1373 
  1374 
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Finally, we assessed the selective advantage before and after the TERT promoter mutation, 1375 
s0 and sTERT, as (Bozic et al., 2016) 1376 
   (33) 1377 
   (34) 1378 
 1379 
QUANTIFICATION AND STATISTICAL ANALYSIS 1380 
Statistical tests 1381 
To measure differences in the mutational burden of primary and relapsed glioblastomas, we 1382 
employed a two-sided Welch two sample t-test on the 17 non-hypermutated tumor pairs. The 1383 
distribution of methylated and unmethylated MGMT promoters between tumors with mono- or 1384 
oligoclonal relapse origins was assessed with a hypergeometric distribution (n=21, corresponding 1385 
to the tumors of the discovery set). Differential gene expression between tumors and normal brain 1386 
tissue was analyzed with the R package DESeq2 1.18.1 (Love et al., 2014); differential expression 1387 
was accepted for Benjamini-Hochberg-corrected p values < 0.01.  1388 
All statistical parameters shown in figures are detailed in the figure legends.  1389 
 1390 
Software 1391 
Phylogenetic inference and modeling of evolutionary dynamics were performed on R 3.3.1 (R Core 1392 
Team, 2017), using the libraries doParallel, foreach and phangorn. The R libraries AnnotationsDbi, 1393 
DESeq2, FlowSorted.DLPFC.450k, FlowSorted.Blood.450k, GenomicRanges, Hmisc, Homo.sapiens, 1394 
MCP-counter, minfi, phangorn, phyloTop, phytools, YAPSA and xlsx were used for data analysis and 1395 
the libraries beeswarm, colorlovers, colorspace, ComplexHeatmaps, ggplot2, igraph, pheatmap, 1396 
plotrix and RColorBrewer were used for plotting. Plots were redesigned in Adobe Illustrator CS5. All 1397 
other software used is mentioned in METHOD DETAILS. 1398 
 1399 
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DATA AND SOFTWARE AVAILABILITY 1400 
Sequencing data have been deposited in the European Genome-phenome Archive (EGA) under 1401 
the accession number EGAS00001003184. R codes for phylogenetic inference and modeling of 1402 
clonal dynamics are available as supplementary files to this paper.  1403 
 1404 
 1405 
Supplementary Tables and Figure legends 1406 
Table S1. Clinical data of the investigated glioblastoma patient cohort. 1407 
 1408 
Figure S1. Tumor and immune cell content, related to Figure 1. 1409 
(A) Estimated tumor cell content in primary and recurrent samples from the discovery set assessed 1410 
with phylogenetic inference. 1411 
(B) Immune cell composition from gene expression profiles (samples are ordered pairwise: left, 1412 
primary; right, relapse tumor). 1413 
(C) Estimated cell type composition of NeuN-positive and –negative cells (left) and immune cells 1414 
(right) from methylation patterns (boxes specify interquartile ranges; horizontal lines indicate 1415 
medians; whiskers extend to the most extreme datapoints that are no more than 1.5 times the 1416 
interquartile range; outliers are represented by circles; data is from 98 samples from both the 1417 
discovery and the validation set).  1418 
(D) Methylation subtypes in primary and recurrent tumors (from 47 pairs of both the discovery and 1419 
the validation set for which methylation subtypes of both samples could be determined). 1420 
 1421 
Figure S2. Mutational profile of primary and relapsed tumors, related to Figure 2. 1422 
(A) Potentially druggable mutations in primary and relapsed tumors of the discovery set (excluding 1423 
hypermutated cases). Shown are mutations (non-synonymous/stop-gain SNVs, homozygous 1424 
deletions, small insertions/deletions and structural variants) found in at least one tumor. Vertical 1425 
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lines separate tumor pairs (left primary, right relapsed); methylation subtypes are indicated at the 1426 
bottom. 1427 
(B) Mutation distribution in the discovery and the validation set for four prominent oncogenes 1428 
(TERT promoter, PTEN, EGFR, TP53; excluding samples analyzed with both methods). 1429 
 1430 
Figure S3. Phylogenetic inference from whole genome sequencing data, related to Figure 3 1431 
and STAR Methods. 1432 
(A-B) Candidate trees for phylogenetic inference. 1433 
(A) Tree templates used to infer the phylogenetic structure. Three examples of unique distributions 1434 
of primary and relapse samples are shown for each tree, if assuming maximally three subclones per 1435 
sample. 1436 
(B) Trees can be collapsed to obtain solutions, in which primary and relapse samples share clones, 1437 
or to topologies representing linear evolution. 1438 
(C-L) Phylogenetic inference on simulated data. Shown are the results from 100 simulations of up 1439 
to three subclones per primary and relapse sample, respectively. 1440 
(C) True and inferred tumor cell content with Pearson’s correlation coefficient. 1441 
(D) True and inferred clone size with Pearson’s correlation coefficient. Shown are only cases, in 1442 
which the correct number of subclones had been called. 1443 
(E) Deviation from the true number of subclones. 1444 
(F, G) False negative and false positive clonal mutations, if neglecting subclones ≤10%. 1445 
(H) True and inferred difference between the most recent common ancestors of primary and 1446 
relapse sample, measured in mutation counts. Pearson’s correlation coefficient is indicated in the 1447 
plot. 1448 
(I) True and inferred mean number of mutations per subclone since the most recent common 1449 
ancestor population of the tumor. 1450 
(K) Sensitivity of detecting a subclone in dependence of the relative subclone size. 1451 
(L) Specificity of detecting a subclone in dependence of the relative subclone size. 1452 
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(M) Comparison of tumor cell content estimates from phylogenetic inference and from ACEseq. 1453 
Pearson’s correlation coefficient is indicated in the plot. 1454 
 1455 
Figure S4. Phylogenetic trees of the discovery set, related to Figure 3. 1456 
Trees are designed as explained in Figure 3 (i.e. vertical branch lengths scale with the number of 1457 
mutations, circle sizes scale with relative subclone sizes; mutations in driver genes and copy 1458 
number changes of chromosomes 7, 9 and 10 are indicated; yellow circles, primary tumor; orange 1459 
circles, recurrent tumor). 1460 
(A-N) Cases with an oligoclonal origin of the relapsed tumor. Panels (K-N) correspond to 1461 
hypermutated cases, where only clonal mutations are indicated. 1462 
(O-S) Cases with a more monoclonal origin of the relapsed tumor. The tree shown in (Q) was due to 1463 
low tumor cell content selected based on the purity estimate by ACEseq. 1464 
Shown are all tumors of the discovery set excluding the three tumors shown in Fig. 3. 1465 
 1466 
Figure S5. Subclonality of TERT promoter mutations and evolutionary dynamics during 1467 
tumor growth, related to Figures 4 and 5. 1468 
(A) Variant allele frequencies (VAFs) of canonical TERT promoter mutations (black), germline 1469 
mutations (grey) and expected VAFs if sampling from a binomial distribution (red). VAFs of TERT 1470 
promoter mutations were adjusted with the average estimate of tumor cell content from 1471 
phylogenetic inference and ACEseq (as shown in Fig. S3M; tumors with non-neutral copy number 1472 
at the TERT promoter were excluded, yielding data from 16 tumor pairs). Germline mutations were 1473 
chosen from all tumors of the discovery set at loci with read coverage within the inter-quartile-1474 
range of the coverage at the TERT promoter (IQR=[106,140], assessed from the 16 pairs of which 1475 
the VAFs at the TERT promoter mutation are shown) and down-sampled to 1,000 loci for better 1476 
visualization. Expected germline VAFs (red) were computed from the average of binomial 1477 
distributions if drawing samples of the measured read coverages with success probability 0.5. 1478 
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 (B) Kernel density estimates of the VAFs at heterozygous germline mutations (grey) and TERT 1479 
promoter mutations (black; the solid line shows the average, the opaque area the 95% confidence 1480 
interval of the kernel density estimate after sampling the tumor cell contents 10,000 times from the 1481 
estimates from phylogenetic inference and ACEseq; displayed data are downsampled as in (A)). 1482 
(C) Reference sequence at the TERT promoter (red, canonical SNVs; black, germline SNP). 1483 
(D,E) Measured (points) and predicted (lines) cumulative distributions of VAFs at canonical TERT 1484 
promoter mutations and a germline SNP (solid lines, binomial distribution at the lower 25% 1485 
quantile of the measured coverage; red lines, 95% lower confidence bound at the lower 25% 1486 
quantile of the measured coverage). 1487 
(D) Heterozygous germline SNP (1295349 A>G) in the discovery set (median coverage=140x, 1488 
IQR=[130x,156x]; displayed data are from eight tumor pairs in which the polymorphism was 1489 
found).  1490 
(E) Canonical TERT promoter mutations in the discovery set (VAFs are corrected for tumor cell 1491 
content; median coverage=97x, IQR=[77x,114x] after correcting for tumor cell content; tumors with 1492 
non-neutral copy number at the TERT promoter were excluded, yielding data from 16 tumor pairs).  1493 
(F) Immunohistochemical staining for ATRX in a primary and relapsed tumor of a selected patient 1494 
with a frame-shift ATRX mutation and a non-canonical TERT promoter mutation in both tumors 1495 
(antibody binding visualized with diaminobenzidine as chromogen (brown), all sections 1496 
counterstained with hematoxylin (blue), original microscopical magnification: 400x; in total 1497 
samples from four patients were stained of which two are exemplarily shown in (F) and (H)). Note 1498 
loss of nuclear ATRX expression in both tumor samples. Interspersed vascular endothelia serve as 1499 
endogenous control with retained nuclear ATRX expression.  1500 
(G) TERT expression (RNA-seq read counts normalized by library size) in normal brain tissue samples 1501 
(grey dots; normal brain tissue data were generated by The Cancer Genome Atlas (TCGA) research 1502 
network: http://cancergenome.nih.gov/), a tumor pair with non-canonical TERT promoter mutation 1503 
(red dots) and in tumors with canonical TERT promoter mutations (black dots). ATRX expression of 1504 
the tumor pair with non-canonical TERT promoter mutation is shown in (F). 1505 
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(H) Nuclear ATRX expression in a primary tumor without ATRX mutation and retention of nuclear 1506 
ATRX expression in the relapsed tumor of the same patient with a non-synonymous SNV in ATRX. 1507 
Staining and magnification as in (F). 1508 
 (G) TERT expression (RNA-seq read counts normalized by library size) in normal brain tissue 1509 
samples (grey dots; normal brain tissue data were generated by The Cancer Genome Atlas (TCGA) 1510 
research network: http://cancergenome.nih.gov/), a tumor pair with non-canonical TERT promoter 1511 
mutation (red dots) and in tumors with canonical TERT promoter mutations (black dots). ATRX 1512 
expression of the tumor pair with non-canonical TERT promoter mutation is shown in (C). 1513 
(I) Mean number of mutations per primary subclone accumulated after the most recent common 1514 
ancestor of the tumor (shown are the tumors of the discovery set, excluding hypermutated 1515 
samples; red line, median). 1516 
(K) Relative contribution of the clock-like mutational signature AC1 to mutations residing at the 1517 
trunk and the tips of the phylogenetic trees (separately for primary and relapse subclones from 1518 
cases of the discovery set, excluding hypermutated samples; red lines, median). 1519 
(L) Fraction of cell death per cell division required to reconcile an observed number of subclonal 1520 
mutations with a tumor size of 109 cells (red line, median number of mutations per subclone 1521 
observed in the data if excluding hypermutated cases; shaded area, inter quartile range). 1522 
(M) Genes associated with positive regulation of cell death (GSEA: GO:0010942, from 1523 
http://software.broadinstitute.org/gsea/msigdb/), which were differentially expressed (p<0.01 after 1524 
Benjamini-Hochberg correction) between tumors (n=36) and normal brain tissue controls (n=5, 1525 
normal brain tissue data were generated by The Cancer Genome Atlas (TCGA) research network: 1526 
http://cancergenome.nih.gov/). Shown are log2 fold changes between tumor and control. 1527 
(N, O) Residual sum of squares when comparing the mean and variance of measured and modeled 1528 
TERT promoter-mutant tumor fraction at different values of δ0 and δTERT (grey dashed lines, 1529 
bisetrices; data are from 19 tumors of the discovery set with canonical TERT promoter mutation). 1530 
For each point the simulated mean and variance of 1000 simulations were compared to the 1531 
measurement. Shown are the results if implementing TERT promoter mutations at the somatic 1532 
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mutation rate (N) and four-fold the somatic mutation rate (O). Estimates lying within the 95% 1533 
confidence interval (corresponding to a  ) are shaded in dark red. These parameter 1534 
combinations give equally good fits. Black lines mark the fractions of cellular death required to 1535 
explain tumor sizes of 109 cells (as shown in (L)). This fraction is required for both the TERT 1536 
promoter-mutant tumor fraction and the tumor fraction without TERT promoter mutation. Since 1537 
δTERT ≤ δ0, it is sufficient to require the cutoff for δTERT, corresponding to the horizontal line. Thus 1538 
parameter estimates explaining both, the TERT promoter-mutant tumor fraction and mutation 1539 
accumulation in tumors of realistic sizes, intersect the horizontal black line and are colored in dark 1540 
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Table S1. Clinical data of the investigated glioblastoma patient cohort. 
 Entire cohort (n=50) WGS cohort (n=21) 
Age at diagnosis (years) 
  Median (range) 60 (14 – 80) 60 (33 – 78) 
Gender 
  Male 35 (70%) 11 (52%) 
  Female 15 (30%) 10 (48%) 
Tumor location 
  Frontal 11 (22%) 4 (19%) 
  Temporal 18 (36%) 6 (29%) 
  Parietal 5 (10%) 3 (14%) 
  Occipital 3 (6%) 1 (5%) 
  More than 1 cerebral lobe 13 (26%) 7 (33%) 
  Local relapse 48 (96%) 20 (95%) 
Extent of initial surgery 
  Gross total resection 20 (40%) 11 (52%) 
  Subtotal resection  29 (48%) 10 (48%) 
  No data 1 (2%) - 
MGMT promoter methylation, primary tumor 
  Methylated 21(42%) 11 (52%) 
  Unmethylated  27 (54%) 10 (48%) 
  No data 2 (4%) - 
MGMT promoter methylation, recurrent tumor 
  Methylated 23 (46%) 12 (57%) 
  Unmethylated 27 (54%) 9 (43%) 
  No data - - 
DNA methylation subgroup, primary tumor 
  RTK I 11 (22%)    6 (29%) 
  RTK II 19 (38%) 10 (48%) 
  Mesenchymal 16 (32%) 4 (19%) 
  H3-G34  2 (4%) 1 (5%) 
  No data 2 (4%) - 
DNA methylation subgroup, recurrent tumor 
  RTK I 9 (18%)  4 (19%) 
  RTK II 16 (32%) 9 (43%) 
  Mesenchymal 22 (44%) 7 (33%) 
  H3-G34  2 (4%) 1 (5%) 
  No data 1 (2%) - 
First-line therapy 
  Radiotherapy alone 5 (10%) 1(5%) 
  Temozolomide alone 1 (5%) 1 (5%) 
  Radiotherapy plus temozolomide 42 (84%) 19 (90%) 
  No therapy beyond surgery 3 (6%) - 
Survival data (days), median (range) 
  Interval between first and second surgery  
  Overall survival  
  Patients alive at last follow-up 
290 (35 -1500) 
518 (147 – 3168) 
25 (50%) 
280 (46 - 994) 
580 (261 - 1783) 
10 (48%) 
Abbreviations used: WGS, whole genome sequencing; RTK I, receptor tyrosine kinase I group; RTK II, receptor 
tyrosine kinase II group; H3-G34, H3F3A-G34-mutant group.	
	
Figure S1. Tumor and immune cell content, related to Figure 1. 
(A) Estimated tumor cell content in primary and recurrent samples from the discovery set assessed with 
phylogenetic inference. 
(B) Immune cell composition from gene expression profiles (samples are ordered pairwise: left, primary; right, 
relapse tumor). 
(C) Estimated cell type composition of NeuN-positive and –negative cells (left) and immune cells (right) from 
methylation patterns (boxes specify interquartile ranges; horizontal lines indicate medians; whiskers extend to 
the most extreme datapoints that are no more than 1.5 times the interquartile range; outliers are represented by 
circles; data is from 98 samples from both the discovery and the validation set).  
(D) Methylation subtypes in primary and recurrent tumors (from 47 pairs of both the discovery and the validation 





















































































































Figure S2. Mutational profile of primary and relapsed tumors, related to Figure 2. 
(A) Potentially druggable mutations in primary and relapsed tumors of the discovery set (excluding 
hypermutated cases). Shown are mutations (non-synonymous/stop-gain SNVs, homozygous deletions, small 
insertions/deletions and structural variants) found in at least one tumor. Vertical lines separate tumor pairs (left 
primary, right relapsed); methylation subtypes are indicated at the bottom. 
(B) Mutation distribution in the discovery and the validation set for four prominent oncogenes (TERT promoter, 
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Figure S3. Phylogenetic inference from whole genome sequencing data, related to Figure 3 and STAR 
Methods. 
(A-B) Candidate trees for phylogenetic inference. 
(A) Tree templates used to infer the phylogenetic structure. Three examples of unique distributions of primary 
and relapse samples are shown for each tree, if assuming maximally three subclones per sample. 
(B) Trees can be collapsed to obtain solutions, in which primary and relapse samples share clones, or to 
topologies representing linear evolution. 
(C-L) Phylogenetic inference on simulated data. Shown are the results from 100 simulations of up to three 
subclones per primary and relapse sample, respectively. 
(C) True and inferred tumor cell content with Pearson’s correlation coefficient. 
(D) True and inferred clone size with Pearson’s correlation coefficient. Shown are only cases, in which the 
correct number of subclones had been called. 
(E) Deviation from the true number of subclones. 
(F, G) False negative and false positive clonal mutations, if neglecting subclones ≤10%. 
(H) True and inferred difference between the most recent common ancestors of primary and relapse sample, 
measured in mutation counts. Pearson’s correlation coefficient is indicated in the plot. 
(I) True and inferred mean number of mutations per subclone since the most recent common ancestor 
population of the tumor. 
(K) Sensitivity of detecting a subclone in dependence of the relative subclone size. 
(L) Specificity of detecting a subclone in dependence of the relative subclone size. 
(M) Comparison of tumor cell content estimates from phylogenetic inference and from ACEseq. Pearson’s 
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Figure S4. Phylogenetic trees of the discovery set, related to Figure 3. 
Trees are designed as explained in Figure 3 (i.e. vertical branch lengths scale with the number of mutations, 
circle sizes scale with relative subclone sizes; mutations in driver genes and copy number changes of 
chromosomes 7, 9 and 10 are indicated; yellow circles, primary tumor; orange circles, recurrent tumor). 
(A-N) Cases with an oligoclonal origin of the relapsed tumor. Panels (K-N) correspond to hypermutated cases, 
where only clonal mutations are indicated. 
(O-S) Cases with a more monoclonal origin of the relapsed tumor. The tree shown in (Q) was due to low tumor 
cell content selected based on the purity estimate by ACEseq. 






































































































































































































































































































































Figure S5. Subclonality of TERT promoter mutations and evolutionary dynamics during tumor growth, 
related to Figures 4 and 5. 
(A) Variant allele frequencies (VAFs) of canonical TERT promoter mutations (black), germline mutations (grey) 
and expected VAFs if sampling from a binomial distribution (red). VAFs of TERT promoter mutations were 
adjusted with the average estimate of tumor cell content from phylogenetic inference and ACEseq (as shown in 
Fig. S3M; tumors with non-neutral copy number at the TERT promoter were excluded, yielding data from 16 
tumor pairs). Germline mutations were chosen from all tumors of the discovery set at loci with read coverage 
within the inter-quartile-range of the coverage at the TERT promoter (IQR=[106,140], assessed from the 16 
pairs of which the VAFs at the TERT promoter mutation are shown) and down-sampled to 1,000 loci for better 
visualization. Expected germline VAFs (red) were computed from the average of binomial distributions if 
drawing samples of the measured read coverages with success probability 0.5. 
 (B) Kernel density estimates of the VAFs at heterozygous germline mutations (grey) and TERT promoter 
mutations (black; the solid line shows the average, the opaque area the 95% confidence interval of the kernel 
density estimate after sampling the tumor cell contents 10,000 times from the estimates from phylogenetic 
inference and ACEseq; displayed data are downsampled as in (A)). 
(C) Reference sequence at the TERT promoter (red, canonical SNVs; black, germline SNP). 
(D,E) Measured (points) and predicted (lines) cumulative distributions of VAFs at canonical TERT promoter 
mutations and a germline SNP (solid lines, binomial distribution at the lower 25% quantile of the measured 
coverage; red lines, 95% lower confidence bound at the lower 25% quantile of the measured coverage). 
(D) Heterozygous germline SNP (1295349 A>G) in the discovery set (median coverage=140x, IQR=[130x,156x]; 
displayed data are from eight tumor pairs in which the polymorphism was found).  
(E) Canonical TERT promoter mutations in the discovery set (VAFs are corrected for tumor cell content; median 
coverage=97x, IQR=[77x,114x] after correcting for tumor cell content; tumors with non-neutral copy number at 
the TERT promoter were excluded, yielding data from 16 tumor pairs).  
(F) Immunohistochemical staining for ATRX in a primary and relapsed tumor of a selected patient with a frame-
shift ATRX mutation and a non-canonical TERT promoter mutation in both tumors (antibody binding visualized 
with diaminobenzidine as chromogen (brown), all sections counterstained with hematoxylin (blue), original 
microscopical magnification: 400x; in total samples from four patients were stained of which two are 
exemplarily shown in (F) and (H)). Note loss of nuclear ATRX expression in both tumor samples. Interspersed 
vascular endothelia serve as endogenous control with retained nuclear ATRX expression.  
(G) TERT expression (RNA-seq read counts normalized by library size) in normal brain tissue samples (grey 
dots; normal brain tissue data were generated by The Cancer Genome Atlas (TCGA) research network: 
http://cancergenome.nih.gov/), a tumor pair with non-canonical TERT promoter mutation (red dots) and in 
tumors with canonical TERT promoter mutations (black dots). ATRX expression of the tumor pair with non-
canonical TERT promoter mutation is shown in (F). 
(H) Nuclear ATRX expression in a primary tumor without ATRX mutation and retention of nuclear ATRX 
expression in the relapsed tumor of the same patient with a non-synonymous SNV in ATRX. Staining and 
magnification as in (F). 
(I) Mean number of mutations per primary subclone accumulated after the most recent common ancestor of the 
tumor (shown are the tumors of the discovery set, excluding hypermutated samples; red line, median). 
(K) Relative contribution of the clock-like mutational signature AC1 to mutations residing at the trunk and the 
tips of the phylogenetic trees (separately for primary and relapse subclones from cases of the discovery set, 
excluding hypermutated samples; red lines, median). 
(L) Fraction of cell death per cell division required to reconcile an observed number of subclonal mutations with 
a tumor size of 109 cells (red line, median number of mutations per subclone observed in the data if excluding 
hypermutated cases; shaded area, inter quartile range). 
(M) Genes associated with positive regulation of cell death (GSEA: GO:0010942, from 
http://software.broadinstitute.org/gsea/msigdb/), which were differentially expressed (p<0.01 after Benjamini-
Hochberg correction) between tumors (n=36) and normal brain tissue controls (n=5, normal brain tissue data 
were generated by The Cancer Genome Atlas (TCGA) research network: http://cancergenome.nih.gov/). Shown 
are log2 fold changes between tumor and control. 
(N, O) Residual sum of squares when comparing the mean and variance of measured and modeled TERT 
promoter-mutant tumor fraction at different values of δ0 and δTERT (grey dashed lines, bisetrices; data are from 
19 tumors of the discovery set with canonical TERT promoter mutation). For each point the simulated mean 
and variance of 1000 simulations were compared to the measurement. Shown are the results if implementing 
TERT promoter mutations at the somatic mutation rate (N) and four-fold the somatic mutation rate (O). 
Estimates lying within the 95% confidence interval (corresponding to a  X
2
≤ 5.99  ) are shaded in dark red. 
These parameter combinations give equally good fits. Black lines mark the fractions of cellular death required 
to explain tumor sizes of 109 cells (as shown in (L)). This fraction is required for both the TERT promoter-mutant 
tumor fraction and the tumor fraction without TERT promoter mutation. Since δTERT ≤ δ0, it is sufficient to require 
the cutoff for δTERT, corresponding to the horizontal line. Thus parameter estimates explaining both, the TERT 
promoter-mutant tumor fraction and mutation accumulation in tumors of realistic sizes, intersect the horizontal 
black line and are colored in dark red. The corresponding values for δ0 are marked by vertical lines. 
	
